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ABSTRACT
Genetic and environmental factors impact colorectal cancer incidence [2, 3].
Environmental factors include fiber intake and exercise, which are both postulated to reduce
colorectal cancer risk [4-6]. While much is understood in regards to how fiber and its derived
nutrients influence inflammation; little is known about how inflammation influences how
nutrient impact cell metabolism and physiology.
The short chain fatty acid butyrate, is derived from the fermentation of fiber in the colon
and is the preferred energy substrate for colonic epithelial cells (colonocytes) [7, 8]. Butyrate
also slows cell proliferation in cancerous colonocytes through its ability to inhibit histone
deacetylases (HDACs) [20]. HDACs are enzymes that remove acetyl groups from histones [9].
Inhibition of HDACs results in hyperacetylation, which leads to changes in gene expression [10].
In cancerous colonocytes, inhibition of HDACs by butyrate induces cell cycle arrest, in part, via
increased p21 expression [10]. Cancer cells deficient in p21 have been reported to be resistant to
butyrate’s anti-cancer effects [11]. Thus, blocking p21 induction by butyrate would promote
tumor development and may exclude the beneficial effect derived from a high fiber diet toward
prevention of the disease.
Patients with colorectal cancer have elevated serum levels of pro-inflammatory cytokines
[12-14]. Pro-inflammatory cytokines have been shown to suppress butyrate metabolism in
cancerous colonocytes [18]. In addition, colorectal cancer patients have a significant reduction in
butyrate producing bacteria [15-17]. The significance of this reduction is unclear, however,
taken in conjunction with decreased butyrate metabolism it is likely to impact of butyrate’s antiproliferation activity in the colon.
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Identification of mechanisms that mediate decreased butyrate metabolism may aid in the
understanding of fiber’s role in colorectal cancer. Here, we find that IL-1[beta] dampens butyrate
metabolism in colorectal cancer cells. Furthermore, IL-1[beta] decreases butyrate’s ability to
slow cell proliferation. We identify two mechanisms by which IL-1[beta] induces these effects.
First, we determine that IL-1[beta] is operating through its receptor, IL-1RI, and second through
a p38-mediated mechanism. These findings are consistent with previous reports that proinflammatory cytokines promote cancer cell survival and proliferation [19-22].
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CHAPTER I

Literature Review and Specific Aims
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Epidemiology
Approximately 1 out of 20 Americans will be diagnosed with colorectal cancer in their
lifetime [1]. The majority of people diagnosed are over fifty years of age [2]. More than half of
the cases will occur in “Westernized” regions of the world [2]. Incidence rates are not
proportional to gender, as men are more likely to develop colorectal cancer than women [3].
Chemotherapeutic treatments, surveillance and lifestyle interventions have led to a decline in
colorectal cancer incidence in individuals over the age of 65 [4]. Survival is highly dependent
upon disease stage at the time of diagnosis [3, 5]. The majority of colorectal cancers occur
sporadically and it is largely thought to be caused by “environmental factors,” [3, 5, 6]. It is
estimated that more than half of all cancers and deaths are preventable through lifestyle
interventions such as diet and exercise [3].

Risk Factors
Genetic and environmental factors influence colorectal cancer incidence. Factors such as
age, gender, personal history with adenomatous polyps, family history of colorectal cancer, race,
and inflammatory bowels disease are non-modifiable [1, 3, 6]. Physical activity, obesity,
cigarette smoking, alcohol consumption and diet are factors that can be modified reduce
colorectal cancer risk [3, 6]. Data suggests that up to 35% of cancer related deaths can be
attributed to diet and related factors [7]. For example, evidence based research shows that a diet
with a high intake of dietary fiber is associated with decreased colorectal cancer incidence [711].
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Dietary Fiber
Dietary fiber is composed of indigestible polysaccharides derived from plants [12]. It
includes soluble and insoluble fiber [12], where both can be fermented by colonic microbes to
provide short chain fatty acids as energetic substrates used by colonocytes [13, 14]. Associations
between dietary fiber and reduced risk of colorectal cancer have been around since the 1970’s
[15]. Epidemiological and experimental studies have provided evidence that dietary fiber has a
protective effect against colorectal cancer incidence [4, 7, 8, 16, 17]. The relative risk derived
from these experimental data is shown in Fig. 1.1. Relative risk is the rate or risk of the outcome
of the intervention group divided by the rate of outcome in the control group [18]. A relative risk
of one denotes that the intervention has no effect [18]. If the risk is below one, then the outcome
is determined to have a positive or good outcome, whereas those that have a relative risk of
above one, are seen to denote harm or poor outcome as compared to control group [18]. In Fig.
1.1, a summary of 16 studies determines that the relative risk of developing colorectal cancer
after consuming dietary fiber is approximately 0.86 (p<0.05) [8]. Thus, there is a significant
inverse association between developing colorectal cancer and consuming dietary fiber [8].
Despite many studies showing that dietary fiber has an inverse association with
development of colorectal cancer, it is controversial. For example, fiber does not appear to
confer a protective effect for individuals that develop colorectal cancer before the age of 65 [3,
5]. Confounding factors such as body mass index, income status and even marital status can
muddle findings and result in the (statistical) loss of the protective effect [3, 19]. Regardless,
based on the evidence, The American Institute of Cancer Research recommends that
consumption of dietary fiber [20]. How fiber inhibits colorectal cancer development and the
mechanisms that contribute to this protective effect are not well understood
3

Background: Current Pathophysiology of Colorectal Cancer
The twentieth century brought forth the current, “genetic mutation model,” of cancer
[21]. In 1953, Carl Nordling’s applied mathematical modeling demonstrated for the first time,
“that the cancerous cell contains not one, but a number of mutated genes,” [21]. Alfred Knudson
further developed this theory by applying statistical analysis on childhood cases of
retinoblastoma [22]. This directly established that with the accumulation of mutations or “hits”
cancer can occur. As such colorectal cancer is a multistep process [23]. The majority of which,
occur sporadically through a series of aberrant and stochastic somatic mutations [24]. Given the
complexity of colorectal tumorigenesis, a brief review of current theories is needed to
characterize sporadic tumorigenesis.

Loeb’s Mutator Phenotype
At this point in time, the idea that the accumulation of “hits” produced cancer required
further explanation as it did not characterize all types of cancers. Therefore, a new model was
adapted to help explain how tumors could acquire mutations that would promote survival. This
model described that DNA polymerase could be altered and result in poor reading of the DNA
and by extension assemble new, daughter DNA with copious mutations [25]. Normally, DNA
rearrangement is tightly controlled, but in cancer cells this can be mutated and lead to aberrant
changes to cell regulation checkpoints [25-27]. The altered DNA polymerase would show a high
degree of infidelity resulting in a high mutation rate; deemed the “mutator phenotype,” [27]. The
tumor cells with the mutator phenotype have point mutations, microsatellite instability, and loss
of heterozygosity [26]. The subsequent genotypes of mutated cells have two fates; 1) lethal
mutants that do not survive to replicate; 2) show an established selective advantage of traits that
4

are passed down to daughter cells [25]. These daughter cells display selective traits that promote
cancer cell survival [25].
The evolutionary process of pruning daughter cells to promote survivability and confer
selective advantage highlights the need for specific mutations. This allows them to bypass
control systems that normally dictate healthy cell replication [27]. It is through genetic instability
that mutations are acquired over generations [26-28]. These tumors are products of the original
mutator phenotype with newly selected survival traits [26, 28]. This is thought to give rise to
tumors that are highly heterogeneous [26, 27]. The pruning of advantageous daughter cells
reveals that tumorigenesis takes time. This is of importance as the number of successful
mutations is thought to take years. Consequently, number of “hits” will increase as a projection
of time [24]. Hence, the rate of colorectal cancer incidence increases with age [5, 6].

Vogelstein’s model of adenoma to carcinoma
The seminal understanding of these selective advantages became apparent within the
literature hereafter. Eric Fearon and Bert Vogelstein published their pioneering paper in June
1990 that focused on identifying these advantages and traits [51]. They defined our current
understanding of colorectal tumor initiation, promotion, and progression [29]. They proposed
that tumors arise from the activations of oncogenes and inactivation of tumor suppressor genes
within colonic epithelial cells [29]. The progression of normal to neoplastic tissue is due
mutations in four to five genes such as Ras and Apc genes [29]. Clinical evidence has determined
that mutations in these genes allow cancer cells to evade regulatory signaling pathways [29]. The
overall effect leads to net cell growth of tumors with selective advantages that avoid normal cell
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cycle check points [29]. These tumors show a loss of regulatory functions [30]. For example,
genetic mutations of regulatory proteins such as p53, Apc, HIF-1, and PI3K are common in many
cancers [30]. The accumulation of these events escalate the transition from neoplasms to
malignant tumors [29]. The Vogelgram (Fig. 1.2) demonstrates, over time, a theoretical process
that hyperplastic colonocytes might utilize during tumorigenesis [29].
The common thread that becomes pervasive throughout the dissemination of the literature
is that cancer is a genetic disease that results from the accumulation of stochastic mutations over
the course of time. Cancer cells evolve by selective advantage through mutations that manipulate
the tumor microenvironment to drive their malignant progression. The accumulation of hits and
selective advantages are important in metastasis. Characterization of these traits and their effects
are important for therapeutic purposes.

Hallmarks of Cancer
During the 1990’s, the general understanding of tumorigenesis had shifted to a multistep
process with four to seven stochastic, genetic aberrations resulting in malignancies [25, 29, 3133] . Over the course of the next decade, research further characterized the heterogeneous nature
of tumors resulting in the publication of Hanahan and Weinbergs’ influential “Hallmarks of
Cancer” in 2000.The “hallmarks” were distilled into “six essential alterations,” that characterize
cancer progression [34]. They described these traits as evading apoptosis, self-sufficiency in
growth signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative
potential, and tissue invasion and metastasis [34]. A decade later, two more hallmarks and
“enabling characteristics,” were added [57]. These new hallmarks include deregulating cellular
6

energetics and avoiding immune destruction [57]. The enabling characteristics are genome
instability mutations and tumor-promoting inflammation [35]. These hallmarks work in concert
to create an ideal, heterotypic microenvironment that provides the selective advantages necessary
for tumor survival [34-37]. Therefore, it is important and necessary to characterize these
hallmarks as they may be utilized for therapeutic purposes.
Of the new hallmarks published in 2011, two are important within the focus of my
research: the deregulation of cellular energetics and tumor promoting inflammation. It is known
that cancer cells can deregulate cellular energetics by shifting their preference for nutrient
metabolism [38]. Recent findings have shown that pro-inflammatory cytokines influence cancer
cell metabolism [38-41]. Very little is available regarding the mechanism(s) by which proinflammatory cytokines influence cellular energetics, especially in colorectal cancer.
Specifically, the effect that IL-1β has on butyrate metabolism in the colonocyte.

Chronic Inflammation and Tumor Promotion
Inflammation can be characterized as the complex biological response to pathogenic or
harmful stimuli [51]. It can be facilitated by a wide variety of mediators including proinflammatory cytokines as a response to harmful stimuli i.e. cancer cells [51]. Inflammation is
considered an enabling characteristic of cancers and promotes the pathogenesis of many human
carcinomas including breast, esophageal, pancreatic, and colorectal [35, 36, 42]. Proinflammatory cytokines are, in part, mediators of the inflammatory process [39, 41, 43, 44].
Serum levels of pro-inflammatory cytokines are elevated in colorectal cancer patients and are
associated with a poor prognosis [45, 46]. Elevated pro-inflammatory cytokines, such as TNF-α
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and IL-1β, stimulate signaling pathways that propagate more inflammation [47]. This feed
forward loop is known to enable tumorigenic activity such as invasion and metastasis [48].
Furthermore, TNF-α has been shown to alter nutrient utilization [49]. The long term effect of this
is unknown but may promote cancer progression. It is to the end that the mechanisms by which
pro-inflammatory cytokines alter cancer cell metabolism to promote survival are necessary to
study.
The role of inflammation in tumorigenesis is strongly supported by research-based
evidence [50-53]. The more robust associations arise in patients with inflammatory bowel
diseases, such as Crohn’s or ulcerative colitis [42]. These rank among the top three risks for
developing colorectal cancer [41, 47, 54]. Other inflammatory disease states such as pelvic
inflammatory disease or Hepatitis C are associated with increased risk of ovarian or liver cancer
[42]. Often times animal models are used for discovering and validating inflammatory
mechanisms that influence the transformation of normal tissue to neoplastic growth [42, 55].
For example, nude mice subcutaneously implanted with adenoma cells do not develop
any malignant growths [56]. However, when the same cells are implanted with a small piece of
plastic, mice show robust tumor growth [56]. Histological analysis of these tumors reveal a
highly proliferative, fibrous stroma within the tumors [56] The authors postulate, that the
irritating piece of plastic promoted a localized immune response by stimulating an inflammatory
response and thus promote the tumorigenic process. This suggests that inflammation is a
necessary component for neoplastic cells to transform into tumors [56].
Moreover, individual pro-inflammatory cytokines, the mediators of inflammation, can be
sufficient enough to induce carcinogenesis [57-60]. For example, polymorphisms in the IL-1β
gene are often accompanied by an increase in IL-1β serum levels [61]. This is linked to an
8

increased risk of gastric cancer [59]. As such, IL-1β transgenic mice develop spontaneous gastric
inflammation, neoplasia, and eventually carcinoma [60]. Overexpression of IL-1β in these mice
causes an accelerated progression of gastric carcinoma [60]. These findings indicate that IL-1β
can stimulate cancer progression, suggesting that inflammation, induced by IL-1β, may be
sufficient to stimulate cancer initiation and progression.
Conversely, in the absence of inflammatory factors, tumorigenesis does not appear and
the incidence of cancer is significantly reduced [50, 51, 62, 63]. For example, mutant TNF-α
knockout mice develop fewer skin lesions and tumors upon exposure to chemical carcinogenesis
[64-66]. Interleukin 1-β converting enzyme (ICE) knockout mice, show a reduction in colorectal
tumorigenesis [67]. These findings indicate the pro-inflammatory cytokines facilitate cancer
progression. Therefore, inhibition of their activity results in decreased tumor maturity and
number [39, 68]. To this end, mice receiving anti-inflammatory pharmaceutical interventions
display fewer, less mature tumors [41, 50, 62, 69]. Likewise, when the transgenic mice overexpress IL-1β are treated with IL-1RA, a natural antagonist of IL-1β, display a significantly
reduced inflammatory and neoplastic response [61]. Even dietary interventions are shown to
reduce carcinogenesis. Mice fed tributyrin, a butyrate analog, are less susceptible to colonic
adenoma formation in chemically induced colorectal carcinoma models [70]. This indicates that
butyrate confers a protective effect. These data suggest that inflammatory factors, such as proinflammatory cytokines, enable carcinogenesis and as such attenuation of their signaling can
reduce neoplastic incidence and progression. In short, elucidation of the mechanisms that
influence tumorigenesis may provide important insight into colorectal cancer formation.
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Interleukin-1
IL-1β is part of the interleukin-1 cytokine family [71]. There are three forms of IL-1: IL1α, IL-1β and IL-1RA derived from the same gene through alternative splicing [71, 72]. Clinical
evidence suggests that the pro-inflammatory cytokine, IL-1β, is associated with tumorigenesis
[71-75]. IL-1β stimulates invasion and metastasis in cancers [39, 76]. IL-1β is elevated in the
serum of colorectal cancer patients and is associated with poor prognosis [77-79]. Interestingly,
the human body has two naturally occurring mechanisms by which IL-1β activity can be
restricted. The first being the expression of a decoy receptor that does not transduce signal and
the second being the expression of IL-1RA which can block IL-1β from binding to the IL-1RI
receptor [71].

IL-1RA
Interleukin 1 receptor antagonist or IL-1RA can bind to the type I receptor and block any
other agonists from binding. The binding of IL-1RA to the type I receptor is not fully
understood, but it thought to have an important role in blocking the pleiotropic effect of IL-1β
[72, 80, 81]. Polymorphisms in the IL-1RA gene have been associated with colorectal cancer
incidence [82]. The use of the recombinant form of IL-1RA, Anakinra, has demonstrated its
value as a natural anti-inflammatory protein in animal and human models for decades [72, 73,
80, 81]. IL-1RA knockout mice display signs and symptoms consistent with arthritis, arteritis,
and skin inflammation, thereby suggesting its role to combat the effects of IL-1α and IL-1β in
vivo [83-86]. Likewise, deficiency in IL-1RA, due to homozygous mutations, results in skin
lesions and bone malformations suggesting that it is necessary to combat the signal transduction
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and inflammatory effects of IL-1β and IL-1α [83, 87]. Animal models that overexpress IL-1β
have accelerated progression of tumors [99], and is attenuated by IL-1RA administration [61].
These findings suggest that IL-1RA has its own mechanisms of action in addition to blocking IL1β’s signal transduction. IL-1RA’s ability to block IL-1β’s activity is of significance and has
been identified as a potential therapy in the prevention and treatment of colorectal cancers [72,
73, 81, 88, 89].

IL-1 Receptors
There are two primary IL-1 receptors, interleukin type I and type II (IL-1RI and IL-1RII)
[72]. Alternative splicing results in the two primary receptors [72, 90]. The functional receptor,
IL-1RI, is expressed in high concentration on endothelial, smooth muscle and epithelial cells [72,
91]. It is expressed in colonocytes and in the HCT116 colorectal cancer cell line [92].
IL-1RII acts as an inert, “decoy,” or “sink” receptor and does not appear to transduce
signal [72, 80, 81, 88, 93]. The type II receptor has a high affinity for IL-1β compared to type I
receptor. This suggests that any IL-1β binding to the decoy type II receptor reduces the amount
of IL-1β binding to the (signal-transducing) type I receptor [72]. Healthy humans show a tenfold
higher presentation of IL-1RII to IL-1RI [72]. The relative binding capacity for the three IL-1
ligands are as follows for type I receptor IL-1Ra> IL-1α> IL-1β and type II IL-1β>IL-1α>IL1RA [72].
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IL-1β
IL-1β is also known as endogenous pyrogen, granulocytic pyrogen, leukocytic pyrogen,
leukocytic endogenous mediator, lymphocyte activating factor, hemopoietin-1, and osteoclast
activating factor [71]. It was the first interleukin studied as a fever-inducing molecule [85]. It
was cloned in 1984 [71, 94]. IL-1β is synthesized in a precursor form before being cleaved by
cytosolic IL-1β-converting enzyme (ICE) to its active form [95]. It is considered a major
upstream pro-inflammatory cytokine that acts as an “alarm” by inducing a cascade of chain
reactions [88]. Upon cleavage, IL-1β, is secreted from the cell where it can target its receptor, IL1RI [71, 96].

IL-1β Signal Transduction
IL-1β activates IL-1RI upon binding as shown in Fig. 1.3. It stimulates an intracellular
signal transduction cascade that targets the mitogen activated kinases (JNK, ERK ½ and p38),
their transcription factor c-Jun and the transcription factor NF-kβ via its subunits p65 and/or p50
[97]. IL-1β is unique among the cytokines, in that the body produces a receptor antagonist to
counteract IL-1β’s effect [71, 93]. IL-1RA blocks IL-1β from binding to IL-1RI, thereby
inhibiting intracellular signaling [73, 80, 81, 93].
p38
p38, also known as mitogen-activated protein kinase (MAPK), is an intracellular target of IL-1β

signal transduction [96, 98-101]. The p38 MAPK is a family of serine/threonine protein kinases that
play important roles in cellular responses to external stress signals such as inflammation [96, 102, 103].
p38 plays a role in cell cycle regulation, metabolism, survival pathways, and cell differentiation[98, 99,
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101]. p38 is a 38 kDa protein that can be rapidly phosphorylated in response to many types of stimuli
including IL-1β [103]. There are four splice variants of p38 which include an α, β, γ, and δ [98,

99, 101]. Isoforms α and β are ubiquitously expressed [98]. However, the γ and δ are
differentially expressed and are dependent on the tissue type [98]. Inhibition of p38 suppresses
IBD and attenuates colorectal cancer progression [99, 101, 104, 105]. It is to this end that
understanding the mechanisms by which p38 influences colorectal cancer progression are of
importance.

p38 and Colorectal Cancer
One of the hallmarks of cancer is the evasion of regulatory signaling resulting in
uncontrolled proliferation [35]. The accumulation of these hallmarks result in deregulation of
signaling pathways that regulate cell cycle [34, 35]. p38 is just one of many pathways that
regulates the balance between apoptosis and cell survival [98, 99]. It is often “hijacked” by
cancer cells as a means of evading regulatory signals [99]. p38 is associated with tumor growth
in many cancers including colorectal [105, 106]. For example, patient derived colorectal cancer
xenografts treated with p38 inhibitors show reduced net growth as compared to their untreated
counterparts [100]. This suggests that p38 supports net cell growth and overall tumorigenesis.
Interestingly, p38 isoforms appear to have differing roles in tumorigenesis. For example, p38γ
knockout mice demonstrate rapidly increased tumorigenesis compared to their WT controls
[103]. This alludes to a protective effect for p38γ. Likewise, p38α KO mice showed significantly
more tumors and increased tumor burden size as compared to their WT controls [107]. These
data reveal that p38 isoforms may suppress cancer progression. This may be linked to cancer cell
metabolism, as p38 is associated with stimulating a metabolic shift in colorectal cancers that
13

sustains cancer cell proliferation [105, 108]. It is to this end that cancer cells demonstrate the
ability to commandeer intracellular signaling pathways i.e. p38 to stimulate cancer cell
metabolism.

IL-1β and carcinogenesis
Inflammation and pro-inflammatory cytokines have long been implicated for their role in
colorectal cancer pathogenesis [35, 39, 41, 42, 45, 73, 109-112]. “Smoldering” inflammation is a
phrase often used to describe the subclinical inflammation that is associated with colorectal
cancer [112, 113]. Smoldering inflammation supports the pathogenesis of colorectal cancer
through a wide variety of mechanisms [111-114]. These include chemokine recruitment,
angiogenesis, matrix remodeling, and tumor cell proliferation [114].These survival mechanisms
are, in part, controlled by pro-inflammatory cytokines signaling such as TNF-α or IL-1β [111116]. IL-1β is a key modulator of these survival pathways and has been used in vivo numerous
times to demonstrate its role in inflammation-induced tumor progression [59, 85, 86, 95, 96, 117121]. For example, matrix metalloproteinases (MMPs) are enzymes required for normal
extracellular matrix turnover and tissue remodeling [122]. MMP7 is associated with
inflammatory processes that can contribute to tumorigenesis specifically colorectal cancers
[123]. Metalloproteinase-7-deficient (MMP-7(⁻ ⁻ ) mice have a three-fold higher intestinal
baseline of IL-1β (~20 vs 60 pg/mL) [123]. These mice are more susceptible to dextran sulfate
sodium (DSS) induced colitis as compared to control mice [123]. Both wild type and mutant
mice were treated with 4% DSS for 9 days, both developed severe colitis, however the mutant
mice died on day nine due to the severity of their colitis [123]. This suggests that the increased
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baseline inflammation (as denoted by the three-fold increase in baseline IL-1β) induced an
exacerbated response to the treatment and therefore expedited disease progression [123]. MMPs
are thought to contribute to IL-1β degradation [122]. This suggests, that the increase in baseline
IL-1β in the matrix metalloproteinase (MMP) KO may be a result of decreased IL-1β turnover
[109]. These findings suggest that IL-1β expedited the progression and severity of DSS-induced
colitis and therefore, appear to play a significant role in inflammation based disease models.
To illustrate this further, a single dose of IL-1β prior to injection of tumor cells increases
the colonization of malignant cells in the lungs [120, 121]. This demonstrates that IL-1β
encourages metastasis via stimulation of adhesion molecules such as intercellular adhesion
molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) [83, 128]. These data
exemplify IL-1β’s ability to stimulate survival traits in cancer cells promote tumorigenesis. To
this end, a reduction its signaling pathway seems imperative to inhibit or slow the progression of
cancer. Interestingly, dietary nutrients, such as butyrate, reverse pro-inflammatory-cytokine
induced adhesion molecule formation [124-126]. Butyrate also inhibits the activation NFkβ, an
intracellular inflammatory signaling protein, by preventing its translocation to the nucleus [127,
128]. These functions may contribute to butyrate’s anti-cancer effects. It is to the end that as IL1β and butyrate have overlapping cell signaling properties, it is important to understand the
effect they have in concert.

Crossroads of Inflammation and Diet
Clinical research strongly suggests the protective effects that diet and dietary components
have in preventing cancer [129]. For example, increased dietary fiber intake has been shown to
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aid in the reduction of “flare-ups” in patients with CD and IBD [130]. The mechanism(s) of
action is still not fully understood [133]. One mechanism may be butyrate; as butyrate enemas
are one of the most effective treatments for IBD in the clinic [13, 131, 132]. Butyrate has been
shown to mitigate inflammatory responses within colonocytes [126, 128]. Interestingly, butyrate
metabolism has been shown to be down-regulated in IBDs and colorectal cancer [49, 133-136].
The long term effects of this are unclear, but may be associated with mitigating the pro-cancer
effects of pro-inflammatory cytokines. Pro-inflammatory cytokines are found to be upregulated
in IBDs and colorectal cancer [77, 137]. Pro-inflammatory cytokines have been shown to shift
colonocyte metabolism away from butyrate utilization [49, 52, 110, 138]. Therefore,
understanding the function of pro-inflammatory cytokine induced mechanisms that perturb
butyrate metabolism could yield key insight into colorectal cancer pathology and prevention.

Dietary Fiber and Butyrate Metabolism
The gastrointestinal tract is inhabited by microorganisms that have a
symbiotic/mutualistic relationship with its host [139]. These trillions of microorganisms ferment
indigestible matter such as resistant starches, unabsorbed sugars, and polysaccharides [140, 141].
Within the colon, this indigestible matter can be fermented to form short chain fatty acids that
provide 10-30% of the total ingested energy [140]. Without these microbes, as in the case of
germ free mice, they must consume 10-30% more food to maintain the same body weight as
conventionally raised mice (those with normal microbiota) [141]. Despite the germ free mice
consuming more food, their epididymal fat pads are nearly half the size of their microbiomeladen counterparts [141, 142]. Suggesting the role of the microbiome and its fermentation
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products such as butyrate, contribute to overall health is a significant one. It is to this end that
changes in luminal butyrate concentration may affect human health. Recent evidence has
demonstrated that there is a reduction in butyrate producing bacteria in patients with IBDs and
colorectal cancer [135, 143]. The implications of this reduction are unclear, but may accentuate
the unique role of butyrate in preventing IBD and colorectal cancer.
As early as the 1970’s, observational research noted that Africans have much lower
incidence of colorectal cancer and this is thought to be due to their increased fiber intake as
compared to a Western diet (Fig. 1.4) [15]. A number of theories were proposed regarding this
effect [32]. First, the dilution of carcinogens within the stool mass could lead to less interaction
with the intestinal epithelia [32]. Second, there could be a decrease in transit time for the stool
mass [32]. Third, fermentation of fiber could result in a reduction of colonic pH due to the
production of short chain fatty acids [32]. This is supported by clinical research. For example,
additional intake of 10-30 grams of fermentable fibers increases short chain fatty acids
production and fecal bulk, resulting in shortened transit times [14].

SCFAs and colonocyte health
The fermentation of dietary fiber results within the colon in the formation of short chain
fatty acids (SCFAs) [144-146]. SCFAs are organic fatty acids that vary in length from one to six
carbon atoms in various carbon arrangement [14]. Acetate, propionate, and butyrate are found in
high (mM) concentrations within the colon [145]. Fecal SCFAs are produced in the following
order of acetate > propionate ≥ butyrate with approximately 60:20:20 for their molar ratio in the
colonic lumen [14]. They are principal anions which aid in absorption, lower pH, and maintain
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luminal osmolarity maintenance [14]. These SCFAs are significant sources of energy in the
colon and suppress glucose and glutamine oxidation [145, 147]. They regulate colonocyte
metabolism which in turn regulates colonocyte growth, differentiation, and proliferation [34]

Acetate
Acetate is the principal SCFA in the large intestine [14, 145, 147]. Acetate is readily
absorbed in the colon. It is metabolized in the colon, but the majority (50-70%) is used by the
liver for hepatic cholesterol synthesis and lipogenesis [14]. The expression of acetyl-CoA
synthetase in adipose and liver catalyzes the formation of acetyl CoA; the first step in activation
of lipogenesis [14]. In fact, subjects given rectal infusions of acetate show a dose dependent
increase in the levels of serum cholesterol and triacylglycerols (TAGs) [14]. Accordingly, the
formation of lipid products from acetate supplementation promotes cellular proliferation and
increased oxidation in the cancerous colonocyte cell line, HT-29 [148]. The effects of acetate on
lipogenesis can be further amplified in the presence of glucose with one and a half more acetate
incorporated into lipid formation than when butyrate is present in the colonocyte [148].
Furthermore, acetate can increase histone acetylation, but is not a histone deacetylase inhibitor as
butyrate is, and therefore, it does not possess the same growth inhibitory properties as butyrate in
cancerous colonocytes [148].

Propionate
Propionate is a three-carbon SCFA produced in the colon [145, 147]. It is absorbed more
readily than acetate in the colon [14]. The liver has been shown to have a 90% uptake of
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propionate as opposed to 75% of acetate via the portal vein [14]. Furthermore, colonic infusions
of propionate promote gluconeogenic pathways, whereas acetate increased serum cholesterol and

glucagon, and reduced free fatty acids [149]. This suggests that propionate may play a role in
cholesterol synthesis inhibition and regulate gluconeogenesis via its conversion to succinyl CoA
in the mitochondria [14, 150].

Butyrate
Butyrate, a four-carbon fatty acid, plays a key role in colonocyte health and homeostasis
as shown in Figure 1.5 [14, 145]. It is the primary energy source of colonocytes [145, 147].
Butyrate regulates the maturation and differentiation of colonocytes [147]. In the case of
colorectal cancer, butyrate induces cell cycle arrest and apoptosis in cancerous colonocytes [14,
134, 151]. This is due to cancerous colonocytes having altered butyrate metabolism (suppression
of oxidation), which changes the fate of butyrate and form diminishment of its anti-cancer
properties [49, 152-155]. These mechanisms are not fully understood. However, evidence
suggests that this may be, in part, due to the presence of pro-inflammatory cytokines which alter
butyrate’s metabolic fate [155]. Understanding the mechanisms that affect butyrate homeostasis
in the colon are important to understand its role in prevention and treatment of colorectal cancer.

Butyrate’s concentration in the lumen of the colon
Gut microbiota contribute to the acquisition of energy within their human host by
fermenting what would otherwise be non-digestible sources of carbohydrates into short chain
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fatty acids such as acetate, propionate and butyrate as shown in Fig. 1.5 [133, 156-158]. Total
short chain fatty acid contents can reach approximately 100 mM in the gut lumen [133, 158].
Butyrate is found in very high concentrations [mM] within the lumen of the colon [158]. A
concentration gradient is formed as butyrate passes through the unstirred water layer and down
into the crypt [158]. Thus, higher butyrate levels exist in the lumen and diminish as butyrate
moves down the crypt structure. Colonocytes in the crypt function to lower butyrate levels by
oxidizing it as an energy source [159]. Thereby, lowering the concentration as butyrate moves
down the crypt which, in turn, promotes stem cell proliferation. Butyrate uptake by colonocytes
is mediated by a solute carrier family 16 member (SLC16A1), also known as monocarboxylic
acid transporter 1 (MCT1) [136]. Upon uptake in the colonocyte, butyrate can be utilized as an
energy source or a HDAC inhibitor [145].

Butyrate as a primary energy source
Isolated colonocytes display different oxidative capacities depending on the metabolic
substrate [145]. Radiolabeled glucose and/or butyrate contribute to 59% and 72%, respectively,
of the oxygen consumption in isolated colonocytes [145]. These findings demonstrate that the
colonocyte prefers butyrate as a primary energy source [145]. Following uptake by the
colonocyte as shown in Fig. 1.6, butyrate is metabolized in the mitochondria to form two acetyl
CoA molecules [136]. The resulting acetyl CoA molecules enter the Krebs Cycle to eventually
produce ATP or contribute acetyl groups for lipogenesis or histone acetylation [136, 148, 160,
161]. In the presence of 5 mM glucose, butyrate is mainly used for oxidation [144]. However, at
higher concentrations (>5mM) butyrate can play a unique role in histone modification by
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inhibiting histone deacetylases [152]. Butyrate is unique among the short chain fatty acids for its
duel functions that contribute to histone modification and colonocyte metabolism [162].

Butyrate and histone acetylation
Histone acetylation is an epigenetic mechanism that regulates gene expression as shown
in Figure 1.7 [70, 133, 163, 164]. Histone acetylation is regulated by acetyl groups, histone
acetyltransferases (HATs) and histone deacetylase (HDACs). HATs catalyze the addition of
acetyl groups and HDACs catalyze the removal of acetyl groups from lysine tails within histones
[13, 133, 156]. HDACs are classified into four classes (I-IV); butyrate inhibits classes I, II and
III [162, 165, 166]. Interestingly, butyrate affects the activity of both HATs and HDACs [152,
162]. Butyrate provides acetyl groups that stimulate HAT activity. In addition, butyrate inhibits
HDAC activity resulting in histone hyperacetylation [152, 162]. The resulting histone
hyperacetylation regulates gene expression by altering chromatin organization [162, 167]. This
allows induction or repression of certain genes, including cell cycle regulation proteins such as
p21 [162, 168-171]. Butyrate’s ability to hyperacetylate histones affects only 2% of gene
expression [162]. Despite this small amount, that 2% is crucial in colonocyte health and
regulation [13]. This transcriptional regulation promotes maturation and differentiation in
normal, healthy colon cells [13]. Yet, in cancerous colonocytes butyrate induces cell cycle arrest
and even apoptosis [162]. This dichotomy is known as the butyrate paradox [152, 172].
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Butyrate’s mechanism of growth restriction of cancerous colonocytes
Butyrate has been extensively studied for its growth arresting properties in cancerous
colonocytes [13, 133, 156, 161, 167-171, 173-179]. For example, treatment of as low as 2 mM
butyrate can inhibit cell proliferation in HT-29 cells, a colorectal cancer cell line [148]. Yet,
acetate at concentrations as high as 10 mM does not produce this same effect [148]. In fact, it has
the reverse effect, acetate stimulates tumor cell proliferation by increasing the available acetyl
groups that are necessary for lipogenesis that contribute to new cell turnover [148]. Acetate is
used elucidate butyrate’s short chain fatty effects [14, 145, 148, 149, 156, 158], but it does not
inhibit cell proliferation as butyrate does. Different effect between these two SCFAs highlight
the fact that the mechanisms by which butyrate inhibits cancer cell proliferation need to be
further clarified [156, 161, 173, 176-179].
Butyrate’s ability to inhibit HDAC activity results in hyperacetylation and transcriptional
regulation [13, 177]. Butyrate stimulates hyperacetylation of the p21 promotor region resulting in
increased p21 expression and subsequently cell cycle regulation in cancerous colonocytes [169171, 174]. To separate butyrate’s short chain fatty acid effect from its HDAC inhibition activity,
trichostatin A (TSA) is often used [162]. TSA inhibits HDAC activity in a very similar manner
to butyrate [13, 168]. As such, TSA and butyrate both stimulate expression of p21 through the
same mechanism of HDAC inhibition [13, 162, 180]. Therefore, butyrate’s ability to stimulate
cell cycle regulation is dependent upon its ability to inhibit HDAC activity [169-171, 174, 181],
not due to its short chain fatty acid effects on metabolism [148].
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p21
At high concentrations (>5mM), butyrate can inhibit HDAC activity leading to elevated
p21 expression in colorectal cancer cells [13, 152]. The eukaryotic cell cycle is controlled by two
families of proteins: the cyclins and cyclin dependent kinases (CDKs) [171, 182]. These proteins,
in part, regulate the progression of cell growth and cell cycle arrest [168]. For example, D
cyclins regulate the G1-S transition phase and bind with its respective CDKs 4 and 6 before
complexing with a retinoblastoma (Rb) protein [162]. This signals the cells to progress into the S
phase [171]. However, in the presence of p21, this progression can be selectively inhibited
causing cell growth arrest and even apoptosis through BAX/BIM mediated pathway as shown in
Fig. 1.8 [171]. Many have demonstrated butyrate’s unique ability to increase hyperacetylation in
the promotor region of p21, thereby increasing its transcription/expression, and subsequently
ability to obstruct cell cycle progression past the G1 phase in cancerous colonocytes [162, 169171, 174].

Murine Models
Butyrate is a byproduct of dietary fiber fermentation, and therefore, its production is
dependent upon the butyrate producing bacteria present within the microbiome. Patients with
colorectal cancer often have less butyrate producing bacteria [135, 183, 184]. The effect of this
dysbiosis is unclear.
Dietary fiber significantly contributes to host energy homeostasis and colonic health, in
part, by being broken down into an energy source by colonic microbiota [70]. For example, germ
free (GF) and conventionally raised (CR) mice (those with a complete microbiome) display
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functional differences in energy metabolism [70]. GF mice must increase their intake by 10-30%
as compared to CR mice to maintain body weight [141, 142, 185]. Colonocytes isolated from GF
mice have significant differences in mitochondrial metabolism (i.e. diminished NADH/ATP
production) and display a different metabolic phenotype compared to CR mice [70].
Interestingly, all of these differences are rescued upon butyrate supplementation [141]. These
findings demonstrate that butyrate plays a fundamental role in colonic health and overall
wellbeing in this animal model. Just as dietary fiber promotes overall colonic health it can also
have a protective effect against colorectal cancer formation. To demonstrate these effects,
chemical induction of colorectal cancer is used in murine models as they are highly reliable and
are easily replicated. A common chemical induction model uses azoxymethane (AOM) to induce
DNA mutations [186, 187]. AOM induced-tumors histologically represent many characteristics
common with human colorectal cancers such as Kras mutations [187]. These tumors form over
months [29, 187-189]. Dextran sulfate sodium (DSS) added to the drinking water dramatically
reduces the latency period of tumor formation [186, 187, 190]. AOM/DSS murine models
replicate an inflammation-based, colitis-like colorectal cancer model.
Dietary fiber and its by product butyrate have a protective effect against adenomatous
polyp formation [70, 188, 190-192]. For example, germ free mice (GF) colonized with or
without butyrate producing bacteria (BPB) show that the mice with BPB had a protective effect
in developing tumors (Table 1.1) [70]. Briefly, mice underwent AOM/DSS treatment to induce
tumorigenesis [70]. Throughout, mice were maintained on low or high fiber diets that were
calorically matched [70]. GF with the BPB had significantly increased luminal butyrate levels
and had significantly fewer tumors than control groups (1 tumor versus 3-4 tumors; Table 1.2)
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[70]. This signifies that a high fiber diet protects against colorectal tumorigenesis in a microbiota
and butyrate dependent manner [70].
To further confirm the tumor suppressive effects of the BPB, the butyrate producing species was
genetically altered to limit the formation of butyrate [70]. In the second round of experiments,
the experimental model showed significantly decreased luminal butyrate and lost the protective
effect of butyrate resulting in increased tumor size and colorectal cancer progression[70].
However, when the same model is used conjunction with a tributyrin supplemented diet, a
butyrate analog, the protective effect is rescued in a microbiota-independent manner [70]. In
addition to this protective effect, these tumors showed significantly reduced size and
histopathologic progression as compared to the control groups [70].
This study establishes that dietary fiber has protective These findings, however, do not
support the role of an inflammation induced tumorigenesis model with butyrate suppressing
neoplastic growth in a murine model [70, 192].

Translating to humans
Highly controlled animal model testing does not always directly translate to human
outcomes. While research based evidence supports the protective role of dietary fiber and SCFAs
[7, 9, 10, 193], its translation into the general population isn’t always as clear. For example,
many factors such as methodology, microbiome, age, gender, and animal model can confound
dietary fiber’s protective association [13, 14, 194]. However, there are association to suggest that
butyrate is advantageous for humans. It is especially pronounced when using butyrate as a
treatment for bowel diseases. For example, fecal samples of patients
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with IBDs show reduced SCFA appearance [195]. Interestingly, when isolated, these colonocytes
show differences in their butyrate oxidation capacity [153]. Moreover, patients undergoing
surgical diversion of their colon frequently develop a condition known as diversion colitis [131].
Supplementation with butyrate enemas in diversion colitis patients, none of whom had previous
evidence of CD, UC, or IBD, resulted in mitigation of inflammatory symptoms and remission
[131]. Likewise, avoidance of dietary fiber has demonstrated increases of “flares” but patients
with IBDs [196]. In CD patients, butyrate supplementation causes a decrease in proinflammatory cytokine expression [128]. These mechanisms by which dietary fiber and its
fermentation byproduct, butyrate, influence pro-inflammatory cytokines signaling are necessary
to illuminate the path of understanding colorectal cancer prevention and treatment.

Specific Aims
In general, the pro-inflammatory based molecular mechanisms that result in decreased
butyrate utilization within cancerous colonocytes are not well defined. Identification of these
mechanisms may aid in the understanding of colorectal cancer treatment and prevention. A major
goal of this research project is to elucidate the effect of the pro-inflammatory cytokine, IL-1β, on
butyrate metabolism in the cancerous colonocyte. More specifically, this research focuses on the
effect of IL-1β on butyrate oxidation and its fate in the cancerous colonocyte. Therefore, these
studies will address the following:
1) Determine whether colon cancer cell metabolism is affected by IL-1β in reference to
butyrate oxidation; and determine if other proinflammatory cytokines affect butyrate
metabolism.
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2) Elucidation the mechanism by which IL-1β shifts colonocyte butyrate metabolism; and
determine if it is specific to the colonocyte.
3) Interrogate downstream consequences of IL-1β’s effect on butyrate metabolism.
The major hypothesis of this work is that butyrate metabolism is altered by the pro-inflammatory
cytokine, IL-1β, and the downstream effects may play an important role in colorectal cancer
progression.
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Appendix

Figure 1.1. “Dose response analysis between for total dietary fiber intake,” Adapted from,
“Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response
meta-analysis of prospective studies,” by Aune et al [8]. A relative risk plot demonstrating that
the increased consumption of dietary fiber has an inverse relationship of developing colorectal
cancer.
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Figure 1.2. A Genetic Model for Colorectal Tumorigenesis. Adapted from Fearon and
Vogelstein’s seminal 1990 paper, “A Genetic Model for Colorectal Tumorigenesis,” that
illustrates the progressions of normal epithelia to malignant through the accumulation of genetic
mutations resulting in metastasis.
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Figure 1.3. IL-1β Signal Transduction Cascade. IL-1β can operate through its type I receptor
(IL-1RI) whereby it activates intracellular signaling pathways such as p38. Activation of these
pathways can modify cell responses such as altered gene transcription.
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Figure 1.4. The proposed effects of fiber. Dietary fiber is proposed to have multiple effects
within the colon. Some of these include increased short chain fatty acid production which can
lead to a decrease in pH. Increased fiber intake is associated with decreased transit time in the
colon. Dietary fiber fermentation leads to an increase in production of short fatty acids which are
the preferred energy source of colonocytes. Finally, dietary fiber promotes dilution of
carcinogens within the matter itself leading to decreased exposure along the luminal wall.

41

Figure 1.5. Fate of Dietary Fiber. Dietary fiber is fermented to form short chain fatty acids that
can be utilized differently in normal versus cancerous colonocytes. For example, in healthy
colonocytes, butyrate promotes differentiation and cellular maturation as it moves up the crypt.
However, in cancerous colonocyes, butyrate can induce decreased proliferation, modified cell
cycle which can lead to cell cycle arrest or even apoptosis [152].

42

Figure 1.6. Butyrate metabolism in the colonocyte. Butyrate is metabolized to form acetyl
CoA in the colonocytes. Acetyl CoA has many fates including histone acetylation through ATP
citrate lyase dependent and independent mechanisms. Butyrate inhibits histone deacetylase
activity by binding to the enzyme and inhibiting its activity, which removes acetyl groups from
histones, thereby allowing hyperacetylation and subsequent gene transcription modification.
Additionally, butyrate stimulates histone acetylase activity by providing acetyl groups as the
substrate for this enzyme.
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Figure 1.7. Butyrate’s role in histone modification and downstream effects. Adapted from
Donohoe et al article, “The Warburg Effect Dictates the Mechanism of Butyrate-Mediated
Histone Acetylation and Cell Proliferation,” depicting the downstream pathways of butyrate
oxidation.
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Figure 1.8. Butyrate mechanisms of growth restriction in cancerous colonocytes. Butyrate
modifies cancerous colonocyte cell cycle by first providing acetyl groups and second by
inhibiting histone deactylase (HDAC) activity allowing histones to become hyperacetylated. This
hyperacetylation leads to gene transcription modification in promotor regions such as p21 and
increases its transcription. Translation of this protein yield cell cycle arrest and apoptosis via
BAX/BIM mediated pathway.
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Table 1.1. A diet high in fiber has a tumor suppressive effect in a microbiota and butyrate
dependent manner. Using AOM/DSS model to induce tumorigenesis, a diet high in fiber and
with butyrate producing bacteria showed a significantly reduced tumor load as compared to
control groups.

Low Dose (1 AOM/2 DSS)
Fiber
Content
BPB

High

Low

High

Low

-

-

+
with B. fib

+
with B. fib

Mouse

GF

GF

GF

GF

Average
tumor #

3-4

3-4

1

3-4
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Table 1.2. Luminal butyrate provides a protective effect against colorectal tumorigenesis. A
diet high in fiber and with butyrate producing bacteria show a protective effect against colorectal
tumorigenesis demonstrating a microbiota and butyrate dependent mechanism. Furthermore, a
diet supplemented with tributyrin, demonstrates a butyrate dependent mechanism that
significantly suppresses colorectal tumorigenesis.

High Dose (5 AOM/3 DSS)
Fiber
Content
BPB

High

Low

-

-
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GF

Average
tumor #
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Low
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B. fib
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CHAPTER II

Characterization of the Pro-Inflammatory Cytokine IL-1β on Butyrate
Oxidation in Colorectal Cancer Cells
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Abstract
Cancer, in part, is driven, by alterations in cellular metabolism that promote cell survival
and cell proliferation. Identifying factors that influence this shift in cellular metabolism in cancer
cells is important. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine that has been reported
to be elevated in colorectal cancer patients. While much is known towards the effect of dietary
nutrients on regulating inflammation and the inflammatory response, which includes cytokines
such as IL-1β, far less is understood how cytokines impact nutrient fate to alter cancer cell
metabolism. Butyrate, a nutrient derived from the fermentation of dietary fiber in the colon, is
the preferential exogenous energetic substrate used by non-cancerous colonocytes, but is used
less efficiently by colorectal cancer cells. To test whether IL-1β alters colonocyte energy
metabolism, we measured butyrate oxidation in HCT116 colorectal cancer cells with and without
IL-1β. We hypothesize that IL-1β will push cancerous colonocytes away from the utilization and
oxidation of butyrate. In this study, we demonstrate that pretreatment of colorectal cancer cells
with IL-1β diminished butyrate oxidation and NADH levels. This effect was blocked with the
interleukin receptor antagonist A (IL-1RA). Moreover, IL-1β suppressed basal mitochondrial
respiration and lowered the mitochondrial spare capacity. By using inhibitors to block
downstream targets of the interleukin-1 receptor pathway, we show that p38 is required for the
IL-1β-mediated decrease in butyrate oxidation. These data provide insight into the metabolic
effects induced by IL-1β in colorectal cancer, and identify relevant targets that may be exploited
to block the effects of this cytokine.
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Background
There is a great body of evidence supporting a direct role of inflammation in promoting
cancer progression [1-3]. Patients with inflammatory bowel disease have an increased risk of
developing colorectal cancer [4, 5]. Colorectal cancer patients have elevated levels of proinflammatory cytokines, including TNFα, IL-6, and IL-1β [6, 7]. IL-1β is an especially
interesting culprit in colorectal cancer development as polymorphisms in its gene are associated
with the disease [8-10]. Further supporting this cytokine’s cancer promoting effect, IL-1β
knockout mice have an increased survival rate and decreased tumor growth in preclinical cancer
models [11]. This also suggests that IL-1β alone can drive tumorigenesis and cancer progression.
Diet is another factor that impacts the development of colorectal cancer [12-14]. Dietary
fiber is thought to inhibit colorectal tumorigenesis, although this has been suggested to be, in
part, due to the production of butyrate [15]. Butyrate is a short-chain fatty acid (SCFA) that is
produced in the colonic lumen through the fermentation of fiber by resident bacteria.
Importantly, butyrate serves as the primary energy source for colonocytes, and it can function as
an histone deacetylase (HDAC) inhibitor at physiologically-relevant doses [16]. Towards this
end, the oxidation of butyrate by the colonocyte appears to be important in regulating butyrate
levels in the cell, which would subsequently regulate HDAC inhibition [16]. Colorectal cancer
cells have diminished butyrate oxidation, and factors such as the Warburg effect and decreased
intracellular carnitine may contribute to the altered metabolic fate of butyrate [15-17].
The cancerous colonocyte shifts cellular metabolism to increase glucose uptake and
utilization. In the clinic, this can be confirmed through positron emission topography (PET)
imaging demonstrating that colorectal tumors take up increased amounts of radiolabeled glucose
[18, 19]. Glucose uptake is further increased as colorectal tumors acquire late stage mutations
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such as Kras and progress toward metastasis, which suggests that changes in cellular metabolism
in the cancerous colonocyte are important for colorectal cancer progression [20]. It is unclear
whether IL-1β enhances colorectal cancer development through altering cellular metabolism.
In this study, we find that IL-1β suppresses the oxidation of butyrate in cancerous
colonocytes. We further define the effects of IL-1β on cancerous colonocytes and demonstrate
that metabolism is shifted away from mitochondrial metabolism. However, glucose metabolism
is also suppressed in these cancer cells when treated with IL-1β. Finally, mechanisms that
regulate the diminishment in butyrate oxidation are explored and p38 is identified as an
important mediator.

Results
IL-1β decreases butyrate oxidation in colorectal cancer cells
The Seahorse XF Extracellular Flux Analyzer is an instrument that measures oxidative
(oxygen consumption) and non-oxidative (glycolysis or lactate production) components of
cellular metabolism [21-23]. We sought to use this methodology to better understand how
inflammatory cytokines such as IL-1β impact cellular metabolism. Specifically, we wanted to
test whether IL-1β would alter the metabolic fate (i.e. oxidation) of butyrate in HCT116
cancerous colonocytes. We previously developed an experimental strategy using the Seahorse
XF Analyzer to measure butyrate oxidation in actively respiring cells (Fig. 2.1A).
To test the effect of IL-1β on butyrate oxidation, we pretreated HCT116 cells with IL-1β
and then measured the OCR. Cells that received butyrate showed a significant increase in OCR
after the addition of 2DG when compared to cells that did not receive butyrate (Fig. 2.1B). This
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is consistent with cells utilizing butyrate, when glucose utilization is inhibited by 2DG. The
increase observed after 2DG injection was abolished in IL-1β treated cells (Fig. 2.1C). Thus, IL1β suppressed butyrate oxidation in this colorectal cancer cell line.

Effect of IL-1β and butyrate on NADH and ATP levels
The oxidation of fatty acids produces reducing equivalents such as NADH and FADH2,
which carry electrons to the electron transport chain complexes that drive ATP synthesis. Since
butyrate oxidation was suppressed by IL-1β, we tested whether NADH and ATP levels were
impacted as a consequence. IL-1β alone induced a significant decrease in NADH levels, but
addition of butyrate rescued this deficit (Fig. 2.2A). This suggested that although butyrate
oxidation was decreased by IL-1β, overall NADH levels are not changed. Consistent with this
interpretation, we observed no significant differences in ATP levels in cells treated with only IL1β or with IL-1β and butyrate (Fig. 2.2B). The difference between IL-1β alone decreasing
NADH, and not ATP may be due to NADH utilization rather than NADH production. It was
unclear whether IL-1β affected mitochondrial function (i.e., basal respiration, spare respiratory
capacity, proton leak, and ATP-coupled respiration).

IL-1β alters mitochondrial function
To test whether IL-1β influences mitochondrial function in HCT116 cells, we performed
a mitochondrial stress assay. In the mitochondrial stress assay, cells are treated first with
oligomycin, which blocks ATP synthase. As a result, protons (H+) are not able to cross from the
inner mitochondrial space into the matrix and proceed down their electrochemical gradient.
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Oxygen consumption drops and the amount of this decrease gives insight into the ATP coupled
mitochondrial respiration. Next, FCCP is injected into the wells. FCCP is an ionophore, which
allows protons to cross into the mitochondrial matrix. This uncouples respiration from ATP
synthesis, and as such, oxygen consumption rises. The degree to which oxygen consumption
rises is equivalent to the spare respiratory capacity. The higher the oxygen consumption rises
then the more electrons are passing through the electron transport chain. Finally, antimycin and
rotenone are injected into the wells to block all mitochondrial respiration and as a result the
oxygen consumption drops. The level to which the oxygen consumption decreases indicates the
contribution of non-mitochondrial metabolism.
Pretreatment of HCT116 cells with IL-1β showed a drastic change in mitochondrial
function as compared to non-treated cells (Fig. 2.3A). Both the basal and spare respiratory
capacity was significantly reduced in HCT116 cells pretreated with IL-1β (Fig. 2.3B).
Furthermore, IL-1β diminished the ATP coupled respiration, while increasing proton leak and
non-mitochondrial metabolism (Figs. 2.3C & 2.3D). These data suggest that IL-1β is decreasing
mitochondrial metabolism in HCT116 cells.

Glycolytic activity is suppressed by IL-1β
The mitochondrial stress test suggested that IL-1β is pushing cellular energetics toward
non-mitochondrial metabolism, which may represent glycolysis. Therefore, we tested whether
IL-1β altered glycolysis in the HCT116 cells. For the glycolysis assay, the extracellular
acidification rate (ECAR) represents the amount of lactate secreted by the cancer cells. Lactate is
a terminal product of glycolysis, and as such, the ECAR measurement is a proxy for glycolytic
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activity. In the assay, glucose is injected, and higher glycolysis is indicated by elevated ECAR.
Oligomycin is then injected to uncouple glycolysis from oxidative phosphorylation, and 2deoxyglucose (2DG) is injected to fully block glucose utilization and glycolysis. IL-1β treated
HCT116 colorectal cancer cells showed a reduced ECAR response after glucose injection (Fig.
2.4A). This was consistent with IL-1β decreasing both glycolysis and the glycolytic capacity in
these colorectal cancer cells (Fig. 2.4B). Thus, we conclude that IL-1β slows cellular metabolism
in HCT116 cancer cells through suppressing mitochondrial metabolism and glycolysis.

Interleukin-1 receptor antagonist rescues butyrate oxidation in IL-1β treated cells
IL-1β binds and signals through the interleukin 1 receptor (IL-1R). The IL-1R receptor
also binds to the endogenously produced interleukin 1 receptor antagonist (IL-1RA), which has
been shown to inhibit IL-1β signaling through the IL-1R [24]. To test whether IL-1β is acting
through the IL-1 receptor to suppress butyrate oxidation, IL-1RA was used to block IL-1β
binding to IL-1 receptor, and therefore, restore butyrate oxidation in the presence of IL-1β. In
these experiments, HCT116 cells were pretreated with IL-1β alone or with IL-1RA for 45 min,
and butyrate oxidation was measured. IL-RA completely rescued IL-1β-mediated reduction in
butyrate oxidation (Figs. 2.5A & 2.5B), while IL-1RA alone did not alter butyrate oxidation
(Figs. 2.5C & 2.5D), suggesting this interaction was specific to IL-1β. We confirmed that IL1RA blocked NFκB activation via IL-1β (as judged by phosphorylation at Ser536) (Fig. 2.8A).
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IL-1β decreases the oxidation of butyrate through p38 and NFκB
NFκB is a downstream target of the IL-1 receptor. Caffeic acid phenethyl ester (CAPE) is
a selective pharmacological inhibitor of NFκB phosphorylation and activation [25]. In our
experiments, we used CAPE to probe the involvement of NFκB in mediating the effect of IL-1β
on suppressing butyrate oxidation. As expected, in HCT16 colorectal cancer cells, CAPE
blocked the activation of NFκB induced by IL-1β (Fig. 2.9A). However, CAPE only partially
rescued butyrate oxidation in cancerous colonocytes pretreated with IL-1β (Figs. 2.6A & 2.6B).
This suggested that NFκB has a role in suppressing butyrate oxidation, however other
downstream molecules to the IL-1 receptor appear to be involved.
IL-1β also signals through p38 via the IL-1 receptor. Treatment of HCT116 cells with
SB203580, a p38 inhibitor, blocked the activation and phosphorylation of p38 by IL-1β (Fig.
2.8B). In addition, SB203580 completely rescued butyrate oxidation in HCT116 colorectal
cancer cells pretreated with IL-1β (Figs. 2.6C & 2.6D). The p38 inhibitor fully rescued the effect
on butyrate oxidation, which suggests that p38 is a key mediator.

Discussion
The effect of IL-1β on cellular metabolism in the cancerous colonocyte has not been
interrogated in detail. Non-cancerous colonocytes utilize butyrate, derived from the fermentation
of dietary fiber, as their primary energetic substrate [26]. Cancerous colonocytes shift toward
elevated glycolysis and glucose utilization [18, 19, 27, 28]. IL-1β decreases the capacity of
cancerous coloncytes to use butyrate, and may represent one mechanism by which this cytokine
alters metabolism to promote cancer progression.
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In this study we measured the acute metabolic response to IL-1β in actively respiring
HCT116 colorectal cancer cells. The concentration of IL-1β in this study was 1 ng/mL, which is
within the physiological range of this cytokine. Blood levels of IL-1β are reported between 100
ng/mL and 1 pg/mL depending on the conditions and external stimuli [29]. Previous work in
colorectal cancer cell lines utilized radiolabelled butyrate and measured its conversion to 14CO2
after a given incubation or exposure time. [30, 31]. Both tumor necrosis factor alpha (TNF-α)
and interferon gamma (IFN-γ) were demonstrated to suppress butyrate oxidation. Interestingly,
TNF-α and IFN-γ activate p38, which we found was important in mediating IL-1β‘s suppressive
effect toward butyrate oxidation. A model constructed from our results illustrates that IL-1β
activates NFκB and p38 pathways to regulate post-transcriptional mechanisms to inhibit butyrate
oxidation (Fig. 2.7).
p38 has been previously linked to colorectal tumor initiation and development [32-34].
Specifically, knockout of the γ isoform of p38 inhibited tumorigenesis in a colitis-associated
mouse model of colorectal cancer [34]. In addition, the p38α isoform has also been shown to
inhibit colorectal tumorigenesis. We demonstrate that a p38 inhibitor rescued the effect of IL-1β
on butyrate oxidation. Our data allude to p38 playing a role in shifting the colorectal cancer cell
away from butyrate utilization or oxidation. p38 has also been associated with resistance to
chemotherapeutic drugs in colorectal cancer cells [35, 36]. Therefore, p38 represents an
interesting chemotherapeutic target that could be exploited to push the colorectal cancer cell
back toward butyrate utilization and enhance the cancer cell’s response to chemotherapeutic
drugs.
Inflammation and diet are two factors that interact to affect colorectal cancer
development [37-39]. Although much is known as to how nutrients impact inflammation, far less
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is understood how inflammatory mediators impact nutrients and their metabolism. Here, we have
identified a mechanism whereby IL-1β stimulates p38, a MAPK kinase, to suppress the oxidation
of butyrate in HCT116 colon cancer cells. Our data suggest that IL-1β signals through IL-1R, to
dampen mitochondrial metabolism, which includes butyrate oxidation. These findings warrant
further investigation into IL-1β’s ability to alter cellular metabolism and determine whether
therapeutic strategies such as using IL-1RA or p38 inhibitors can be used to block these effects
while also inhibiting colorectal cancer progression.

Methods
Cell culture, transfections, and treatment conditions
HCT116 cells (ATCC, CCL-247) were grown in DMEM formulated with 5 mM glucose and
10% FBS. Briefly, cells were incubated for three hours in media (DMEM, 10% FBS, 5 mM
glucose) with one or a combination of 1 ng/mL IL-1β, 10 μM caffeic acid phenethyl ester (NFkB inhibitor; Tocris Cat # 2743), 10 μM SB203580 (p38 inhibitor; Cell Signaling Cat #5633).
All experiments used 1 ng/mL of IL-1β and 5 mM butyrate (final concentration).

Flux experiments
XF24 Analyzer (Seahorse Bioscience) was used to measure the % change in the oxygen
consumption rate (OCR). Experiments were conducted following manufacturer guidelines. Cells
were split and seeded (identical cell number per well) into XF24 cell culture microplates
(Seahorse Bioscience, 100777-004). Before running assay, cells were incubated in KHB (no
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glucose) with or without treatment condition in a 37°C non-CO2 incubator for 45 minutes. After
this time (15 minutes prior to running plate on Seahorse Analyzer), the KHB is exchanged with
fresh KHB (2.5 mM glucose), and the same treatments as described above. Seahorse experiments
were run with identical conditions (unless otherwise noted). Butyrate at 5 mM final
concentration was injected and the change in OCR was measured from baseline (%OCR). Next,
2-deoxyglucose (Sigma, D8375) was injected and %OCR was measured again. Finally, sodium
azide was injected to block oxidative metabolism.
In the mitochondrial stress assay, cells are treated first with oligomycin, which blocks
ATP synthase. As a result, protons (H+) are not able to cross from the inner mitochondrial space
into the matrix and proceed down their electrochemical gradient. Oxygen consumption drops and
the amount of this decrease gives insight into the ATP coupled mitochondrial respiration. Next,
FCCP is injected into the wells. FCCP is an ionophore, which allows protons to cross into the
mitochondrial matrix. This uncouples respiration from ATP synthesis, and as such, oxygen
consumption rises. The degree to which oxygen consumption rises is equivalent to the spare
respiratory capacity. The higher the oxygen consumption rises then the more electrons are
passing through the electron transport chain. Finally, antimycin and rotenone are injected into the
wells to block all mitochondrial respiration and as a result the oxygen consumption drops. The
level to which the oxygen consumption decreases indicates the contribution of nonmitochondrial metabolism.
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Western Blotting
Proteins from HCT116 cells were extracted with RIPA buffer (Cell signaling, #9806), 1 mM
PMSF (Cell signaling, #8553) and phosphatase inhibitor cocktail (Cell signaling, #5872). Protein
concentrations were measured by Bradford assay. Gel electrophoresis and transfer were
conducted using standard protocol for Western blot. Antibodies that were used in experiments
included p38 (Cell Signaling, Cat # 9212S), phospho p38 (Cell Signaling, Cat # 9211S), p65
(Cell Signaling, Cat # 8242P), phospho p65 (Cell Signaling, Cat # 3033P), and β-actin (Sigma,
Cat# A1978). Chemiluminescence detection was performed with the Odyssey Fc and bands were
quantified with Image Studio Software (LI-COR Biosciences, Lincoln, NE).

NADH and ATP Assays
NADH levels in cells were measured with a NADH Assay Kit (Biovision, K334-100). ATP
levels in HCT116 cells were measured with an ATP Fluorometric Assay Kit (Biovision, K354100). For both assays, conditions were kept identical to the Seahorse experiments, and assays
were performed as described by the manufacturer. Prior to each assay, cells were deproteinized
immediately before the assay with a PCA deproteinization kit (Biovision, K808-200).

Statistical Analysis
For biochemical assays, Seahorse Experiments, and Western blots, the differences between
experimental groups were determined by a two-way ANOVA analysis followed by a Tukey post-
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hoc test. All data are expressed as mean  SE. Significant differences were determined by p <
0.05, and are noted in figure legends.

LIST OF ABBREVIATIONS
Interleukin-1β, IL-1β; interleukin receptor antagonist A, IL-1RA; tumor necrosis factor alpha,
TNFα; interleukin-6, IL-6; short-chain fatty acid, SCFA; histone deacetylase, HDAC; positron
emission topography, PET; Krebs-Henseleit Buffer, KHB; oxygen consumption rate, OCR;
extracellular acidification rate (ECAR); 2-deoxyglucose, 2-DG; nuclear factor kappa-light-chain
enhancer of activated B cells, NFκB; c-Jun N-terminal kinases, JNK; extracellular signalregulated kinases, ERK; mitogen-activated protein kinase, MAPK
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Appendix

Figure 2.1. Butyrate oxidation is suppressed by IL-1β in HCT116 cancerous colonocytes.
(A) Schematic representation illustrating rationale used to measure butyrate oxidation with the
XF24 Analyzer. (B) Percent change in oxygen consumption rate (OCR) relative to baseline for
HCT116 cells treated +/- IL-1β followed by injection of butyrate. Total contribution of butyrate
toward OCR (%) is observed after injection of 2-deoxyglucose (2DG). (C) Area under the curve
analysis from OCR measurements taken after 2DG injection, but before azide injection. These
measurements represent the butyrate oxidation (arbitrary units), as butyrate is the only
exogenous oxidative substrate available. Data points represent the average OCR (%) over 3-5
replicates per experimental condition. Bars with the same superscript are not significantly
different at p < 0.01. Error bars are +/- SEM.
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Figure 2.2. IL-1β lowers NADH, but ATP levels are not significantly changed. (A) NADH
levels and (B) ATP levels measured in HCT116 cells treated +/- IL-1β and butyrate. Data points
represent a standard mean where n = 6 per condition. Bars with the same superscript are not
significantly different at p < 0.05. Error bars are +/- SEM.
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Figure 2.3. IL-1β disrupts mitochondrial function. (A) OCR response over time. Oligomycin
was injected to determine the ATP coupled respiration. FCCP was injected to establish the
maximal respiration. Antimycin/Rotenone were injected to define mitochondrial and nonmitochondrial respiration. (B) Calculated basal respiration and spare respiratory capacity. (C)
Contribution of proton leak, ATP-coupled respiration, and non-mitochondrial respiration to
OCR. For these experiments HCT116 cells were treated with or without IL-1β. Each data point
represents the mean value +/- SEM where n = 8 per condition. Bars with the same superscript are
not significantly different at p < 0.05.
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Figure 2.4. Glycolysis is diminished in IL-1β treated colorectal cancer cells. (A) Extracellular
acidification rate was measured after injection of glucose, oligomycin (Oligo), and 2deoxyglucose (2DG). (B) Glycolysis was calculated from the ECAR response to glucose
subtracted from the baseline ECAR before glucose injection. Glycolytic capacity represents the
ECAR measurements before glucose injection subtracted from the ECAR measurements after
oligomycin injection. For these experiments, HCT116 cells were treated with or without IL-1β
45 min prior to assay. Each data point represents the mean value +/- SEM where n = 8 per
condition. Bars with the same superscript are not significantly different at p < 0.05.
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Figure 2.5. IL-1RA completely reverses IL-1β suppression of butyrate oxidation. (A)
Percent change in oxygen consumption rate (OCR) relative to baseline in HCT116 cells treated
with and without IL-1β or IL-1RA. Total contribution of butyrate toward OCR (%) is observed
after injection of 2-deoxyglucose (2DG). (B) Area under the curve analysis is from OCR
measurements taken after 2DG injection, but before azide injection. (C) Percent change in
oxygen consumption rate (OCR) relative to baseline when pretreated with and without IL-1RA.
(D) Area under the curve analysis from OCR measurements taken after 2DG injection, but
before azide injection. For butyrate oxidation measurements data points represent the average
OCR (%) over 3-5 replicates per condition. Bars with the same superscript are not significantly
different at p < 0.05. Error bars are +/- the SEM.
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Figure 2.6. Inhibition of MAPK p38 completely rescues the diminished oxidation induced
by IL-1β. (A) Percent change in oxygen consumption rate (OCR) relative to baseline in
HCT116 cells pretreated with and without IL-1β or caffeic acid phenethyl ester (CAPE). Total
contribution of butyrate toward OCR (%) is observed after injection of 2-deoxyglucose (2DG).
(B) Area under the curve analysis from OCR measurements taken after 2DG injection, but before
azide injection. These measurements represent butyrate oxidation (arbitrary units). (C) Percent
change in oxygen consumption rate (OCR) relative to baseline in HCT116 cells pretreated with
and without IL-1β or SB203580. (D) Area under the curve analysis from OCR measurements
taken after 2DG injection, but before azide injection. For butyrate oxidation measurements data
points represent the average OCR (%) over 3-5 replicates per condition. Bars with the same
superscript are not significantly different at p < 0.01. Error bars are +/- the SEM.
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Figure 2.7. Downstream signaling pathways and targets of IL-1R1. Model showing the
downstream signaling pathways that are activated by IL-1β binding to interleukin-1 receptor 1
(IL-1R1). In this model, IL-1β can signal through NFκB and/or MAP kinases that include p38.
Activation of these pathways by IL-1β can be blocked by IL-1RA. Model was adapted from [40].
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Figure 2.8. Inhibition of IL-1β activation of p65 and p38. Representative western blot
showing (a) phospho – p65 with total p65 and, (b) phospho – p38 with total p38. Conditions
were kept identical to butyrate oxidation experiments and cells were treated for 45 minutes with
cytokines or compounds. Experiments were repeated 2 more times to confirm results.
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Figure 2.9. IL-1β decreases alkaline phosphatase in HCT116 but not HT-29 colorectal
cancer cells. Histogram showing effect of IL-1β treatment on alkaline phosphatase activity,
which serves as a marker of cellular differentiation. Conditions were kept identical to butyrate
oxidation experiments and cells were treated for 45 minutes with IL-1β. Error bars are +/- SEM.
**p < 0.01
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CHAPTER III

Characterization of the metabolic effects induced by pro-inflammatory
cytokines on cancer cell lines
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Abstract
Background: Cancer is, in part driven, by the tumor microenvironment that can promote cell
survival and cell proliferation. Identifying factors that influence this shift in cellular metabolism
in cancer cells is important. Inflammation is described as an “enabling characteristic” of cancer
and is, in part, mediated by pro-inflammatory cytokines. Serum levels of pro-inflammatory
cytokines are increased in many types of cancers. Much is known regarding the regulatory
effects of diet on the inflammatory response. However, far less is understood regarding the effect
of inflammation i.e. cytokines impact on nutrient utilization in cancer cell metabolism.
Literature suggests that inflammation drives cancer progression and may ultimately promote
cancer cell survival. We hypothesized that IL-1β, IL-6, and TNF-α would perturb cancerous cell
nutrient metabolism to promote cell proliferation and survival.
Methods: Butyrate and glucose oxidation in colorectal, melanoma, and prostate cancer cells with
and without IL-1β, IL-6, and TNF-α pretreatment was measured with a Seahorse XF24 Analyzer.
Results: Pretreatment of colorectal, melanoma, and prostate cancer cells with pro-inflammatory
cytokines affected glucose and butyrate oxidation. In non-colon cancer cells, IL-1β did not affect
butyrate oxidation, but did increase endogenous lipid oxidation as compared to untreated cells.
The colorectal cancer cells displayed opposing effects in the presence of pro-inflammatory
cytokines. For example, butyrate oxidation was not suppressed when pretreated with IL-1β in
HT-29 colorectal cancer cells. In contrast, HCT-116 colorectal cancer cells displayed suppressed
butyrate oxidative capacity in the presence of IL-1β and TNF-α. Furthermore, IL-6 enhanced
butyrate oxidation in HCT116 colorectal cancer cells. These data suggest that pro-inflammatory
cytokines modify nutrient metabolism in cancer cells.
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Conclusions: These data provide insight into the metabolic effects induced by pro-inflammatory
cytokines IL-1β, IL-6, and TNF-α in cancer cells, and identify therapeutic options that may be
targeted to block the effects of these cytokines.
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Background
The link between cancer and inflammation was first described by Virchow in the midnineteenth century [1, 2]. The inflammatory response is a known promotor of many cancers,
including colorectal cancer [3-7]. Pro-inflammatory cytokines, mediators of inflammation, such
as IL-6, IL-1β and TNF-α, are elevated in many cancers [8-12]. These pro-inflammatory
cytokines stimulate angiogenesis, adhesion factors, and alterations of nutrient metabolism in
cancer cell lines [13, 14]. A shift in nutrient metabolism could alter cancer cell physiology to
promote survival in cancer cells.
In addition to inflammation, diet promotes or inhibits cancer development [15-19].
Multiple lines of evidence show that diet or nutrients can potentially suppress the inflammatory
response [4, 17, 20]. Conversely, the mechanisms by which inflammatory factors influence
nutrient metabolism have yet to be explored in detail. Pro-inflammatory cytokines such as IL-1β
and TNF-α have been shown to shift cancerous colonocytes away from butyrate metabolism
[14]. This shift away from butyrate metabolism is important in colonocytes as butyrate regulates
cell maturation and differentiation [21]. Furthermore, in cancerous colonocytes, butyrate can
induce apoptosis [22]. Therefore, insight into cytokine-induced molecular mechanisms that
mediate a shift in nutrient utilization away from butyrate metabolism may reveal pathways that
stimulate the transition from normal to neoplastic growth in the colon.
We utilize non-invasive, novel technique to measure the real-time response that proinflammatory cytokines can have on cancer cellular metabolism. Here we find that the proinflammatory cytokine, IL-1β, alters the utilization of glucose, but not butyrate in two noncolorectal cancer cell lines. This suggests that effect of IL-1β is cell type dependent. We also
observe that TNF-α displays a similar effect on butyrate oxidation as IL-1β in HCT116
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colorectal cancer cells. Interestingly, the colorectal cancer cell line HT-29, did not mimic the
butyrate suppressive effect in the presence of IL-1β.

Results
IL-1β effect on butyrate oxidation in A375 cells, a melanoma cell line.
Our strategy to measure butyrate oxidation is shown in Fig. 3.1A. After obtaining the
baseline oxygen consumption rate (OCR), which is exclusively due to glucose oxidation,
butyrate is injected into the wells. After injection of butyrate, glucose and butyrate contribute to
the OCR. To separate glucose and butyrate oxidation, we inject 2-deoxyglucose (2DG), to inhibit
glucose oxidation. Therefore, only butyrate is able to contribute to OCR as it is the only
exogenous energetic substrate available.
To test the effect of IL-1β on butyrate oxidation, we pretreated A375 cancerous
melanocytes with IL-1β and then measured the change in OCR (Fig. 3.1B). Pretreatment with
IL-1β did not affect butyrate oxidation in A375 cancer cells (Fig. 3.1C). Whereas, IL-1β
pretreatment led to increased OCR with non-treated cells (Fig. 3.1C).

IL-1β effect on butyrate oxidation in CWR22Rv1, a castrate resistant prostate carcinoma
cell line
Pretreatment with IL-1β had no effect on butyrate oxidation in CWR22Rv1 cells (Fig.
3.2A & 3.2B). However, pretreatments with IL-1β again (as seen in the melanoma cancer cell
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line) show a significant increase in oxidation as compared to cells without any IL-1β
pretreatment (Fig. 3.2B).

IL-1β effect butyrate oxidation in HT-29, a colorectal cancer cell line.
We sought to test if IL-1β elicited a similar response on butyrate oxidation as it did in the
HCT116 colorectal cancer cells by using HT-29 cells, another colorectal cancer cell line. HT-29
cells pretreated with IL-1β displayed an elevated OCR upon butyrate injection (Fig. 3.3A).
However, upon 2DG injection, cells pretreated with IL-1β do not show any difference in butyrate
oxidation as compared to cell without IL-1β treatment (Fig. 3.3B). This indicates that colorectal
cancer lines respond differently to IL-1β and these difference may reveal insight into how IL-1β
suppresses butyrate oxidation in another colorectal cancer cell line.

Other pro-inflammatory cytokines alter butyrate oxidation in HCT116 cells
IL-6 effect on butyrate oxidation in HCT116s, a colorectal cancer cell line
Since we determined that the exogenous substrate oxidation response to IL-1β was cell
type dependent we next sought to test whether this response was cytokine dependent. Thus, we
chose use HCT116 cells as they displayed a modified butyrate oxidation in response to IL-1β
pretreatment. We first used IL-6 which is a pro-inflammatory cytokine that is also shown to be
upregulated in colorectal cancer [5, 23, 24]. HCT116 cells pretreated with IL-6 had a significant
increase in butyrate oxidation as compared to butyrate treatment alone (Fig. 3.4A & 3.4B).
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Therefore, IL-6 demonstrates that it has the opposite effect on regulating butyrate oxidation as
compared to IL-1β.

TNF-α effect butyrate oxidation in HCT116 cells, a colorectal cancer cell line
Previous work has shown that TNF-α diminishes butyrate oxidation and uptake in HT-29
cells [14]. We next sought to examine if TNF-α would produce similar suppression of butyrate
oxidation in the HCT116 cell line. HCT116 cells pretreated with TNF-α had a significant
decrease in butyrate oxidation as compared to cells without TNF-α treatment (Fig. 5A and &
5B). Therefore, TNF-α is able to mimic the effect of IL-1β on butyrate oxidation in this
colorectal cancer cell line.

Discussion
Research shows that tumors can selectively modify their metabolism and nutrient
utilization to increase their chances of survival [25, 26]. For example, glucose transporter
expression on the cell surface of many cancers is elevated to facilitate glucose utilization [25,
27]. This results in increased glucose uptake, thereby shifting metabolism away from
mitochondrial oxidation and towards glycolysis [28]. Similarly, prostate cancer cells increase
glutamine utilization in order to increase ATP production [26]. These alterations confer a
selective advantage that ensures survival and proliferation of cancer cells [29]. Previous work
from our lab has demonstrated that the pro-inflammatory cytokine, IL-1β, suppresses butyrate
oxidation in HCT116, a colorectal cancer cell line. This is thought to, in part, cause a suppression
of butyrate’s anti-cancer effects. Thus, it is important to characterize the effect that IL-1β may
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stimulate in cancer cell metabolism. As IL-1β diminished butyrate oxidation in HCT116
colorectal cancer cells, we sought to determine if this effect occurred in non-colon cancer cell
lines. Therefore, analyzed a melanoma and prostate cancer cell line to identify whether IL-1β
exerted a similar effect on butyrate oxidation.
The melanoma cell line, A375, did utilize butyrate as denoted by the significant increase
in oxygen consumption rate after butyrate injection. However, pretreatment with IL-1β failed to
reduce butyrate oxidation, suggesting that the IL-1β induced effect observed in HCT116 cells is
cell type dependent. The same trend is observed in the CWR22Rv1 prostate cancer cell line.
Butyrate oxidation is increased, but is not significantly suppressed by IL-1β. Yet IL-1β treatment
after 2DG injection also showed a significantly increased OCR rates as compared to control
groups. These findings suggest that IL-1β significantly induces endogenous lipid oxidation in the
absence of glucose oxidation.
Both non-colorectal cancer cell lines, A375 and CWR22Rv1, oxidized butyrate. While,
IL-1β pretreatment did not suppress butyrate oxidation, it did increase OCR as compared to nontreated cells. In the presence of 2DG, a glycolytic inhibitor, cells that were pretreated with IL-1β
had a significantly increased OCR as compared to groups that did not receive IL-1β
pretreatments. This indicates that the pro-inflammatory cytokine, IL-1β, stimulates a shift in
metabolism towards endogenous lipid oxidation in the absence of glucose. This is important as
cancer cells often outgrow their oxygen supply [28, 30, 31]. To survive, exogenous and
endogenous fatty acid oxidation may be used as a source of energy [26]. The regulation of lipid
metabolism by cancer cells are crucial to their survival [32]. Importantly, cancer cells have been
shown to stimulate lipolysis, fatty acid uptake and β-oxidation from local adipose depots [32,
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33]. Our data support the complex, dynamic shift in cancer cell metabolism that IL-1β can
stimulate to maintain their metabolic potential for cell proliferation in the absence of glucose.
Using HT-29 cells, another colorectal carcinoma cell line, IL-1β pretreated cells did not
suppress butyrate oxidation. Whereas, IL-1β pretreatment did suppress butyrate oxidation in the
colorectal cancer cell line HCT116. This may be due to differences in differentiation, genetic
mutations in these two colorectal cancer cell lines [34]. For example, when both HT-29 and
HCT116 cells are implanted in Matrigel; only the HCT116 are characterized as “highly
aggressive” [34]. They have little to no capability to differentiate [34]. Whereas the HT-29 cells
were able differentiate and form lumens within the Matrigel [34].This phenotypic difference
translates into animal models when HT-29 and HCT116 are used as xenografts. Xenografts of
HT-29 and HCT116 in mice grow at similar rates, but display significant differences in vascular
architecture and proliferation [35]. HT-29 cells display more complex, mature vasculature [35].
Furthermore, differences in the concentration of pro-inflammatory cytokines may affect cancer’s
metabolic profile. Others demonstrate that TNF-α suppresses butyrate oxidation in HT-29 cells
[14]. However, this effect is only seen at five and ten-times the amount of (50-100 ng/mL) of
pro-inflammatory cytokine used in our experiments [14]. These data demonstrate that even
though these are both colorectal cancer cell lines, their differences in geno- and phenotype
expression can influence their nutrient metabolism.
In HCT116 cells, other pro-inflammatory cytokines also have a significant effect on
cancer cell metabolism. IL-6 has been implicated for its role in promoting angiogenesis,
proliferation and migration in colorectal cancer [13]. Pretreatment with IL-6 significantly
increases butyrate oxidation in HCT116 as compared to only butyrate-treated cells. It is unknown
the long-term effect this may have, but butyrate has also been shown to promote colorectal
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cancer cell growth and proliferation in early stage colorectal cancer [36]. Interestingly, IL-6 has
been shown to induce lipolysis in insulin resistant cells or glucose deprived cells [37]. Therefore,
we hypothesize that in the absence of glucose IL-6 may induce increased lipolysis and
subsequent β-oxidation of available substrates-butyrate and endogenous fatty acids. This may be
further explained when comparing IL-6 pretreated cells to cells that received no treatment as the
display a significantly increased OCR.
TNF-α suppresses butyrate oxidation in HCT116 as well as HT-29 cells [14].
Furthermore, the oxidation and uptake of butyrate were significantly decreased in the presence of
TNF-α [50ng/mL] [14]. Cancer cells are known to change their nutrient utilization to increase
their chances of survival [26, 32, 38, 39]. These data establish that pro-inflammatory cytokines
modulate cancer cell nutrient metabolism. We hypothesize that these modulations will promote
cancer cell survival by modifying metabolism to enhance cell proliferation and suppress cell
cycle arrest. This will provide a framework for further characterizing the effect that proinflammatory cytokines elicit from cancer cell metabolism. Furthermore, it may provide an
opportunity for further exploration of therapeutic approaches that inhibit pro-inflammatory
cytokines effects on cancer cell metabolism.

Conclusions
Inflammation has long been linked to cancer initiation and progression [1, 3, 7, 40, 41].
More recently, inflammation has been linked to altering nutrient utilization in cancer cells to
promote cancer cell survival [26]. As such, nutrients play a significant role not only as an energy
source, but also as functional regulators of cells. Here we have identified that pro-inflammatory
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cytokines, mediators of inflammation, alter nutrient utilization in a variety of cancer cell lines.
These findings necessitate the need to further investigate the mechanisms by which proinflammatory cytokines transduce their signal. These findings may aid in the development of
therapeutic strategies to prevent or inhibit tumorigenic progression.

Methods
Cell culture
HCT116 (ATCC, CCL-247), HT-29 (ATCC, HTB-39), and A375 (ATCC, CRL-1619) cancerous
cells, were grown in DMEM formulated with 5mM glucose and 10% FBS. 22Rv1 (ATCC, CRL2505) were grown in RPMI formulated with 5mM glucose and 10% FBS.

Flux experiment
XF24 Analyzer (Seahorse Bioscience) was used to measure % change in the oxygen consumption
rates (% OCR) in HCT116, A375, 22Rv1, and HT-29 cells. Experiments were conducted
following manufacturer guidelines. Cells split and seeded (at an identical cell number per well)
into XF24 cell culture microplates (Seahorse Bioscience, 100777-004) and grown to 90%
confluency in DMEM with only 10% FBS to minimize lipogenesis. Before running the seahorse
assay, cell plates are incubated with 1x KHB (a substrate limited media without glucose with 50
μM carnitine, with or without IL-1β [1ng/mL], TNF-α [10 ng/mL], or IL-6[5ng/mL]) in non-CO2
incubator at 37°C for 45 minutes, then replaced with fresh KHB with 2.5 mM glucose, 50 uM
carnitine, and corresponding cytokines as described above 15 minutes prior to assay. Seahorse

85

experiments were run with identical conditions. Butyrate at 5mM final concentration was
injected and the change in OCR was measured from baseline (%OCR). Next, 2-deoxyglucose
(2DG) (Sigma, D8375) was injected at a final concentration of 5 mM and %OCR was measured
again. Finally, 10% sodium azide was injected to inhibit oxidative metabolism.
Authors’ contributions
MJ and DRD conceived the study design. MJ performed experiments. MJ and DRD prepared
manuscript. All authors read and approved final manuscript.
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Appendix

Figure 3.1. Butyrate oxidation is unaffected by IL-1β [1 ng/mL] in A375 cells, a melanoma
cell line. A. Schematic representation illustrating the exclusive measurement of butyrate
24
oxidation with XF Analyzer using a glucose analog, 2-deoxyglucose (2DG). B. Percent change
in oxygen consumption rate (OCR) in A375 cells pretreated with or without IL-1β (final
concentration 1 ng/mL) and with or without butyrate (final concentration 5 mM). C. Average
OCR measurements of butyrate oxidation taken after 2DG injection, prior to sodium azide
injection. These measurements represent butyrate oxidation (arbitrary units), as butyrate is the
only exogenous oxidative substrate available. Bars with different letters are significantly
different at p <0.01. Data points represent the average OCR (%) over 3-5 replicates per
experimental condition. Error bars are +/- the SD.
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Figure 3.2. Butyrate oxidation is unaffected by IL-1β in CWR22Rv1, a prostate carcinoma
cell line. A. Percent change in oxygen consumption rate (OCR) over time in CWR22Rv1 cells
pretreated with or without IL-1β (final concentration 1 ng/mL) and with or without butyrate
(final concentration 5 mM). B. Average OCR measurements of butyrate oxidation taken after
2DG injection, prior to sodium azide injection. These measurements represent butyrate oxidation
(arbitrary units), as butyrate is the only exogenous oxidative substrate available. Bars with
different letters are significantly different at p <0.01. Data points represent the average OCR (%)
over 3-5 replicates per experimental condition. Error bars are +/- the SD.
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Figure 3.3. Butyrate oxidation is unaffected by IL-1β [1 ng/mL] in HT-29, a colorectal
cancer cell line. A. Percent change in oxygen consumption rate (OCR) over time in HT-29 cells
pretreated with or without IL-1β (final concentration 1 ng/mL) and with or without butyrate
(final concentration 5 mM). B. Average OCR measurements of butyrate oxidation taken after
2DG injection, prior to sodium azide injection. These measurements represent butyrate oxidation
(arbitrary units), as butyrate is the only exogenous oxidative substrate available. Bars with
different letters are significantly different at p <0.01. Data points represent the average OCR (%)
over 3-5 replicates per experimental condition. Error bars are +/- the SD.
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Figure 3.4. Butyrate oxidation is enhanced by IL-6 in HCT116 cells, a colorectal carcinoma
cell line. A. Percent change in oxygen consumption rate (OCR) over time in HCT116 cells
pretreated with or without IL-6 final concentration 5 ng/mL) and with or without butyrate (final
concentration 5 mM). B. Average OCR measurements of butyrate oxidation taken after 2DG
injection, prior to sodium azide injection. These measurements represent butyrate oxidation
(arbitrary units), as butyrate is the only exogenous oxidative substrate available. Bars with
different letters are significantly different at p <0.01. Data points represent the average OCR (%)
over 3-5 replicates per experimental condition. Error bars are +/- the SD.
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Figure 3.5. Butyrate oxidation is diminished by TNF-α in HCT116s, a colorectal carcinoma
cell line. A. Percent change in oxygen consumption rate (OCR) over time in HCT116 cells
pretreated with or without TNF-α (final concentration 10 ng/mL) and with or without butyrate
(final concentration 5 mM). B. Average OCR measurements of butyrate oxidation taken after
2DG injection, prior to sodium azide injection. These measurements represent butyrate oxidation
(arbitrary units), as butyrate is the only exogenous oxidative substrate available. Bars with
different letters are significantly different at p <0.01. Data points represent the average OCR (%)
over 3-5 replicates per experimental condition. Error bars are +/- the SD.
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CHAPTER IV

Interleukin-1 beta regulates p21 induction by butyrate in colorectal cancer
cells through a p38 mechanism
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Abstract
Background: Inflammation is described as an “enabling characteristic” of cancer. Proinflammatory cytokines can mediate the inflammatory response and have been found to be
elevated in many cancers. Pro-inflammatory cytokines have been shown to stimulate a variety of
tumorigenic properties including altering nutrient utilization to promote cancer cell survival and
proliferation. Previously, we have shown that IL-1β, a pro-inflammatory cytokine, suppresses
butyrate oxidation in the colorectal cancer cell line, HCT116. The long term effect of this
remains unclear, but butyrate is known to suppress colorectal cancer cell growth, in part, by
induction of p21. To this end, we hypothesized that IL-1β would perturb butyrate metabolism
decreasing p21 expression and inhibiting cancer cell proliferation.
Methods: The effect of IL-1β on cell numbers was measured with an automated handheld cell
counter. HDAC levels in HCT116 cells was measured with biochemical assays. The action of
cytokines and pharmacological inhibitors were confirmed on downstream targets by
immunoblotting. Furthermore, a Seahorse XF24 Analyzer was used in conjunction with various
pharmacological compounds to assay mitochondrial function
Results: Pretreatment of colorectal pro-inflammatory cytokine, IL-1β suppresses butyrate’s
ability to induce p21 expression. This results in increased cell proliferation as compared to
butyrate treatment alone. Here we show that IL-1β affects butyrate utilization via its receptor and
a p38 mediated mechanism. This effect was completely blocked with the p38 selective inhibitor
203580 and p21 expression was rescued resulting in butyrate induced cell cycle arrest. These
data suggest that IL-1β modifies butyrate metabolism in colorectal cancer cells to promote
cancer cell proliferation.
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Conclusions: These data provide insight into the effects induced by pro-inflammatory cytokine,
IL-1β, the colorectal cancer cell line HCT116, and identify therapeutic targets that may be
exploited to block the effects of IL-1β.
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Background
The short chain fatty acid, butyrate, is derived from microbial fermentation of dietary
fiber in the colon [1, 2]. Butyrate slows cell proliferation in cancerous colonocytes, in part, by
inhibiting histone deacetylases (HDACs) [3-5]. HDACs facilitate the removal of acetyl groups
from histones and inhibition of HDACs results in hyperacetylation of histones [5, 6]. This
hyperacetylation alters gene expression by promoting the relaxation of chromatin [4]. HDAC
inhibition represents one mechanism by which butyrate represses or induces specific genes that
regulate cell cycle progression [4]. It is through the induction of the cell cycle regulatory protein,
p21, that butyrate is able to, in part, inhibit cancer cell proliferation [7-10]. Therefore,
upregulation of p21 by butyrate results in cell cycle arrest in cancerous colonocytes [4, 11, 12].
Outside of elevating histone acetylation, it is unknown what upstream factors regulate this
interaction between butyrate and p21.
Previously, it was found that the pro-inflammatory cytokine IL-1β decreased the
oxidation of butyrate in HCT116 colorectal cancer cells. The significance of this diminished
butyrate oxidation is yet unexplored. The oxidation of butyrate has been previously associated
with mediating colorectal cancer cell cycle regulation and apoptosis through induction, in part, of
p21 [4, 13]. Accordingly, the suppression of butyrate oxidation as mediated by IL-1β would
block butyrate induced p21 expression, which would result in altered cell proliferation in
butyrate-treated cells.
Here, we demonstrate that IL-1β diminishes butyrate’s anti-proliferative activity in
HCT116 cancerous colonocytes. Specifically, HCT116 cancerous colonocytes treated
concomitantly with butyrate and IL-1β showed increased cell proliferation and net cell growth as
compared to butyrate treatment alone. This suggests that IL-1β dampens butyrate’s anti99

proliferative effect, reduces upregulation of p21 by butyrate, and promotes colorectal cancer
progression [14]. Decreasing the capacity of butyrate to induce p21 may represent one
mechanism as to how IL-1β stimulates cancer cell growth and proliferation.

Results
IL-1β suppresses butyrate’s anti-proliferative effect in HCT116 cells
It is unknown whether IL-1β changes the anti-cancer properties of butyrate on colorectal
cancer cells. For initial experiments, we tested the effect of IL-1β on butyrate-mediated
diminishment of cell growth, cell proliferation, and cell viability. In this regard, butyrate
significantly reduced cell growth (Fig. 4.1A and B), cell proliferation (Fig. 4.1C), and cell
viability (Fig. 4.1D) as compared to groups that were not treated with butyrate (control and IL1β). Interestingly, co-incubation with IL-1β blocked the butyrate mediated decrease in cell
growth, proliferation, and viability. These findings suggest that IL-1β suppresses the cell cycle
arrest induced by butyrate. Previously, the cell cycle protein p21 has been implicated in
regulating butyrate’s inhibitory actions on the cell cycle [7, 8]. Therefore, we next sought to test
whether IL-1β impacted p21 induction by butyrate.

IL-1β suppresses p21 expression in the presence of TSA and butyrate
Butyrate and trichostatin A (TSA) are known to induce p21 expression [8, 9]. Butyrate
and TSA induce p21 expression via HDAC inhibition. In agreement with what others have
found, treatment of HCT116 colorectal cancer cells with butyrate (Fig. 4.2A) or TSA (Fig. 4.2B)
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resulted in a rapid upregulation of p21 protein [5, 7-9, 15, 16]. However, butyrate treated cells
simultaneous incubated with IL-1β displayed a significant reduction in p21 expression as
compared to cells treated with only butyrate or TSA. Given that TSA and butyrate inhibit
HDACs and this effect of IL-1β treatment to suppress p21 was observed with both butyrate and
TSA suggests that HDAC inhibition may be important in mediating this effect. Therefore, IL-1β
may affect the ability of butyrate to increase histone acetylation as an HDAC inhibitor.

IL-1β increases histone deacetylase activity in butyrate-treated cells
Butyrate regulates p21 through inhibition of HDACs, which results in global histone
acetylation and histone acetylation at specific promoters [7, 8]. It is unclear whether IL-1β alters
histone acetylation or changes histone acetylation in cells treated with butyrate. HCT116
colorectal cancer cells treated with only IL-1β showed no change in HDAC activity when
compared to controls (cells not treated with IL-1β) (Fig. 4.3A). In contrast, HCT116 cells treated
with IL-1β and butyrate had elevated HDAC activity as opposed to cells treated with butyrate
only (Fig. 4.3B). This same effect was not observed in HCT116 cells treated with IL-1β and TSA
(Fig. 4.3C). Thus, suggesting that HDAC activity may be differentially affected by IL-1β, and it
may not entirely explain IL-1β’s action to suppress p21 induction by butyrate or TSA.

IL-1β affects global H3 acetylation in both butyrate or TSA treated cells
Since IL-1β could alter butyrate’s ability to inhibit HDACs, we next tested whether this
culminated into a change in butyrate induced global histone acetylation. As expected, butyrate
increased global pan H3 acetylation in HCT116 cells (Fig. 4.4A). Consistent with IL-1β
101

interfering with HDAC inhibition by butyrate, HCT116 cells treated with IL-1β and butyrate
exhibited a reduction in H3 acetylation compared to butyrate alone (Fig. 4.4B). Surprisingly,
TSA, which also increased H3 acetylation (Fig. 4.4C), showed a similar response (Figure 4.4D).
Thus, even though IL-1β didn’t alter HDAC activity in the case of TSA, it still was able to
dampen overall global induction of H3 pan acetylation by TSA. This may allude to discordance
between how IL-1β interacts to affect TSA compared to butyrate, in reference to p21 induction.

IL-1β significantly affects gene expression and protein turnover
The fact that butyrate and TSA may regulate p21 protein expression through similar, but
also distinct mechanisms, suggested that both gene expression and protein turnover maybe
important. Thus, RT-PCR was used to test whether IL-1β inhibited p21 gene expression by
butyrate. The p21 gene was significantly induced by butyrate, and this induction was diminished
when co-treated with IL-1β (Fig. 4.5A). To determine how p21 protein turnover was impacted by
butyrate and IL-1β, cycloheximide was used to block gene expression. HCT116 colorectal cancer
cells pretreated for 1 hour with cycloheximide showed elevated p21 protein expression (p21
increased over time) in cells treated with butyrate (Fig. 4.5B). This increase in p21 protein
expression became apparent after 3 hours (Fig. 4.5C). In cells treated with both butyrate and IL1β, p21 protein expression did not increase (Fig. 4.5D). These data suggested that IL-1β is
altering both the p21 gene expression and protein turnover, which again alludes to a mechanism
beyond just IL-1β altering butyrate’s ability to function as an HDAC inhibitor. The mechanisms
by which IL-1β impacted p21 would likely involve downstream signaling proteins of the
interleukin-1 receptor (the major target of IL-1β).
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Inhibition of p38 rescues histone acetylation and p21 expression
We previously found that IL-1β had the ability to decrease butyrate oxidation in
colonocytes through the mitogen-activated protein kinase called p38. p38 is one downstream
target of IL-1R that is activated by IL-1β (Fig. 4.6A). p38 has been shown to positively regulate
p21 through enhancing p53 levels [17]. Towards this end, p21 induction has been linked to
mitochondrial dysfunction and reduced oxygen consumption [18], which are two outcomes we
previously found from IL-1β exposure in butyrate-treated HCT116 colorectal cancer cells. The
reduced oxygen consumption was rescued by blocking the activation of p38 with a selective
pharmacological inhibitor. Thus, in our model we propose that IL-1β reduces p21 induction by
butyrate through activation of p38, and it is possible to negate this effect with a p38 inhibitor,
SB203580 (Fig. 4.6B).
Butyrate or IL-1β activated p38; as judged by the increased phosphorylation of the
protein (Fig. 4.6C) compared to untreated cells. HCT116 cells treated with the combination of
butyrate and IL-1β also showed enhanced p38 phosphorylation, albeit somewhat reduced when
compared to butyrate or IL-1β alone. Importantly, this activation of p38 by both IL-1β and
butyrate was completely abolished in the presence of SB203580, the p38 inhibitor. SB203580
also completely rescued the effect of IL-1β on p21 induction in butyrate treated cells (Fig. 4.6D).
Similar to p38 mediating the effect of IL-1β on suppressing butyrate oxidation, these data
suggest that activation of p38 by IL-1β impacts p21 expression.
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Inhibition of p38 corrects mitochondrial changes induced by IL-1β in butyrate treated cells
To characterize how IL-1β impacts mitochondrial function in regards to butyrate, we
performed a mitochondrial stress assay. IL-1β and butyrate treated HCT116 cells showed an
elevated response to FCCP, which is an ionophore or uncoupling agent, as compared to butyrate
alone (Fig. 4.7A). Treatment of cells with butyrate, IL-1β, and the p38 inhibitor (SB203580)
reduced the response to FCCP to even a lower value than butyrate alone. The major
mitochondrial change that IL-1β effected in butyrate-treated cells was the proton leak, where the
combination of the two increased the mitochondrial proton leak compared to cells treated with
only butyrate (Fig. 4.7B). This effect was completely rescued with the p38 inhibitor. Thus, p38
appears to mediate the mitochondrial changes induced by IL-1β, including the elevated proton
leak, in butyrate-treated cells.
Since the p38 inhibitor blocked IL-1β’s effect on mitochondrial function, we tested
whether this inhibitor would also restore butyrate’s anti-cancer effects in HCT116 colorectal
cancer cells. Thereby associating activation of p38 with mitochondrial alterations induced by IL1β in butyrate treated cells and a cellular outcome such as cell growth. The p38 inhibitor,
SB203580, negated IL-1β protective effect in butyrate-treated cells (Fig. 4.7C).

Discussion
It is well established that butyrate inhibits cell proliferation in cancerous colonocytes by
inducing p21 expression via HDAC inhibition [2, 3, 9, 19]. Factors that disrupt butyrate
metabolism will interfere with HDAC inhibition and butyrate’s anti-cancer effects, including p21
expression. Previously, it was shown that IL-1β suppressed butyrate oxidation. In this study, IL104

1β is demonstrated to block the action of butyrate to decrease cell growth, cell proliferation, and
cell viability, which taken together suggests that this cytokine may alter the beneficial effects of
butyrate to suppress colorectal cancer. These findings are consistent with previous reports that
pro-inflammatory cytokines can stimulate metabolic changes that support cell survival and
proliferation [20-22].
IL-1β is known to promote tumorigenesis by stimulating invasion and metastasis [14].
The mechanisms through which IL-1β stimulates tumor progression remain elusive.
Identification of specific molecular targets that mediate IL-1β-stimulated tumorigenesis would
facilitate the development of therapeutic options to improve prevention and treatment of
colorectal cancer. One potential way IL-1β could impact the effect of butyrate is through
interfering with HDAC inhibition and histone acetylation, especially as it inhibits butyrate
oxidation. Towards this end, IL-1β negatively impacted HDAC inhibition by butyrate, but not by
TSA. Previously, it was reported that diminished oxidation of butyrate is associated with
increased butyrate levels in the cell, and enhanced HDAC inhibition [13, 23]. Based on these
findings, it was predicted that IL-1β, through suppressing butyrate oxidation, would increase
butyrate’s HDAC inhibitory properties and global histone acetylation. However, this was not the
case. This may be due to the fact that previous studies found that butyrate accumulated over time
(24 hours) and many of the outcomes measured in this study occurred within a 3-hour time
window. In fact, the ability of butyrate to increase p21 protein was highest at 3 hours and went
down over extended treatment times (data not shown and [8]). Another factor that may explain
the decrease in HDAC inhibition caused by IL-1β relates to IL-1β impacting butyrate uptake, as
this cytokine has been demonstrated to down regulate the butyrate transporter called
monocarboxylate transporter 1 (MCT1) in colorectal cancer cells [24]. Therefore, diminished
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uptake of butyrate would result in less HDAC inhibition. This is consistent with IL-1β having a
selective effect on HDAC inhibition for butyrate, and not effecting HDAC inhibition by TSA.
Butyrate not only induced the expression of the p21 gene, but also enhanced p21 protein
stability or inhibited degradation of the protein (as judged by the elevated p21 protein levels in
the presence of cycloheximide). These data confirm an earlier study that showed a similar
increase in p21 mRNA when treated with butyrate and cycloheximide in HT-29 colorectal cancer
cells [8]. This study attributes this inability of cycloheximide to stop p21 induction by butyrate
with the association that p21 is an early response gene. However, in this study cycloheximide
was treated concomitantly, whereas in our study we pretreated HCT116 cells 1 hour prior to
butyrate exposure, and then protein levels were measured as opposed to mRNA. Thus, it is
concluded that butyrate inhibits the turnover of p21 protein. Interestingly, IL-1β completely
blocked this effect, once again suggesting that IL-1β is modifying p21 expression by more than
just altering HDAC activity and gene expression.
Previously, p38 was shown to control p21 expression indirectly through regulating p53
levels in human epidermal keratinocytes [17]. HCT116 cancer cells are wild type for the p53
gene, and thus it is possible that through blocking IL-1β activation of p38, p53 induction would
also be inhibited, which would the upregulation of p21. p53 has also been shown to regulate
mitochondrial respiration through altering the electron transport chain (ETC) and oxygen
consumption [25]. This would be consistent with the wide range of mitochondrial perturbations
induced by IL-1β and would link help link the rescue of the p38 inhibitor with mitochondrial
respiration. One issue with the role of p53 relates to the induction of p53 by p38 was reported
after 24 or 48 hours activation, thus it is not clear whether 3 hours following p38 activation is a
long enough period to achieve a significant change in p53 levels. Nevertheless, analyzing the
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role of p53 toward mediating IL-1β’s effects in butyrate treated colorectal cancer cells will be a
priority in future studies.
p38 has already been shown to be a potential valuable target in colorectal cancer
research. Inhibition of p38 inhibits colorectal tumor development and progression in a preclinical
mouse model of colitis-induced colorectal cancer [26]. It is also targeted by important tumor
suppressor proteins, which are known to block the disease [27]. Our data support the current
literature that inflammation induced activation of p38 increases colorectal cancer cell growth and
proliferation. These findings reveal novel insight as to how IL-1β can modulate cancerous
colonocyte nutrient metabolism to support cancer cell survival.

Methods
Cell culture
HCT116 cells (ATCC, CCL-247) were grown in DMEM formulated with 5mM glucose and 10%
FBS. Briefly cells were treated for three hours in treatment media (DMEM, 10% FBS, 5mM
glucose) with one or combination of the following: Butyrate [5mM], IL-1β [1 ng/mL],
SB203580, specific for all p38 isoforms [10uM] (Cell Signaling Cat # 5633), and Cycloheximide
[10ug/mL] (Acros Cat #AC357420010).

Cell Viability Assay/ApoLive-Glo Multiplex Assay
Cell viability was measured according to manufacturer protocol (Promega, Cat #G6410). Briefly,
cells were seeded at equal density in a 96-well plate. The assay measures live cell protease
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activity as a measure of viability by using a fluorogenic, cell permeant, peptide substrate that is
cleaved by proteases to generate a fluorescent signal proportional to the number of living cells.
Conditions were kept identical to previous assay and performed as described in the manufacturer
protocol.

Cell Proliferation Fluorescent Assay
Cell proliferation was measured with a fluorometric assay kit (Biovision K307-1000). Briefly,
HCT116 cells were seeded at equal density in a 96-well. Prior to confluency cells were treated
for 24 hours with corresponding treatments. Conditions were kept identical to previous assay and
performed as described in the manufacturer protocol. Briefly, cells were lysed and a fluorescent
nuclear dye was added 15 minutes prior to plate reading. Fluorescence was read on a plate reader
with Ex/Em 480/538.

Cell Number
Cells were seeded at equal density the prior day to treatments. Cells were treated for 24 hours
with corresponding treatments. Conditions were kept identical to previous assays and performed
as described in the manufacturer protocol. Cells were then trypsonized, pelleted, resuspended
and counted via a handheld automated cell counter, Cell Sceptor by Millipore.
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HDAC inSitu Fluorescent Assay
HDAC levels were measured in HCT116 cells with a HDAC Fluorometric Assay kit (Biovision
K339-100). Conditions were kept identical to previous assay and performed as described in the
manufacturer protocol.

Western Blotting
Proteins from HCT116 cells were extracted with RIPA buffer (Cell signaling, #9806), 1mM
PMSF (Cell signaling, #8553) and phosphatase inhibitor cocktail (Cell signaling, #5872). Protein
concentrations were measured by Bradford assay. Gel electrophoresis and transfer were
conducted using standard protocol for Western blot. Antibodies that were used included p38
(Cell Signaling, Cat # 9212S), phospho p38 (Cell Signaling, Cat # 9211S), p21(Santa Cruz, Cat #
sc-469), β-actin (Sigma, Cat #A1978), pan-acetylated-histone H3 (Active motif, Cat# 39139),
total Histone H3 (Active motif, Cat# 39763), and β-actin (Sigma, Cat# A1978).
Chemiluminescence or fluorescent detection was performed with the Odyssey Fc and bands were
quantified with Image Studio Software (LI-COR Biosciences, Lincoln, NE).

Flux experiment
XF24 Analyzer (Seahorse Bioscience) was used to measure % change in the oxygen
consumption rates (% OCR) in HCT116 and HT-29 cells. Experiments were conducted
following manufacturer guidelines. Cells (HCT116 cells) split and seeded (at an identical cell
number per well) into XF24 cell culture microplates (Seahorse Bioscience, 100777-004). Before
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running seahorse, cell plates are incubated with KHB (no glucose with 50 μM carnitine, with or
without IL-1B, CAPE, SB, IL-1RA) in non-CO2 incubator at 37°C for 45 minutes, then replaced
with fresh KHB with 2.5 mM glucose, 50 uM carnitine, and corresponding treatments as
described above 15 minutes prior to assay. Seahorse experiments were run with identical
conditions (unless otherwise noted). Butyrate at 5mM final concentration was injected and the
change in OCR was measured from baseline (%OCR). Oligomycin(1 uM/mL), FCCP (1
uM/mL, Rotenone and Antimycin (1 uM/mL) were injected from MitoStress test kit (Seahorse
Bioscience, #103015-100).

Statistical Analysis
For biochemical assays and Western blots, the differences between experimental groups were
determined by ANOVA followed by a Tukey post-hoc test. All data are expressed as mean  SE.
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Appendix

Figure 4.1. IL-1β suppresses butyrate’s anti-proliferative effect in HCT116 cells. A. Cell
number measured in HCT116 cells. B. Cell number measured in butyrate and butyrate with IL1β treated HCT116 cells. C. Relative fluorescent units indicative of cell proliferation. D.
Relative fluorescence as a percentage of control measuring cell viability. Data points represents a
standard mean where n = 3+ per condition. Error bars are +/- SEM. Bars with different letters are
significantly different at p<0.05.

113

Figure 4.2. IL-1β suppresses p21 expression in the presence of TSA and butyrate. A.
Western blot and quantification of butyrate induced p21 expression. B. Western blot and
quantification of TSA (trichostatin A) induced p21 expression. Data points represents a standard
mean where n = 3+ per condition. Error bars are +/- SEM. Bars with different letters are
significantly different at p<0.05.
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Figure 4.3. IL-1β increases histone deacetylase activity in butyrate-treated cells. A. Relative
fluorescent HDAC activity in control versus IL-1β treated cells. B. Relative fluorescent HDAC
activity in butyrate versus IL-1β and butyrate treated cells C. Relative fluorescent HDAC activity
in TSA versus IL-1β and TSA treated cells Data points represents a standard mean where n = 5+
per condition. Error bars are +/- SEM. Bars with different letters are significantly different at
p<0.05.
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Figure 4.4. IL-1β affects global H3 acetylation in both butyrate or TSA treated cells. A.
Western blot and quantification of butyrate induced H3ac expression. B. Western blot and
quantification of TSA (trichostatin A) induced H3ac expression. Data points represents a
standard mean where n = 3+ per condition. Error bars are +/- SEM. Bars with different letters are
significantly different at p<0.05.

116

Figure 4.5. IL-1β significantly affects gene expression and protein turnover. A. RT-PCR was
used to test p21 gene expression B. Western blot of p21 with cycloheximide pretreatment C.
quantification of cycloheximide induced p21 turnover expression comparing control and butyrate
groups D. quantification of cycloheximide induced p21 turnover expression comparing IL-1β
and IL-1β and butyrate groups. Data points represents a standard mean where n = 3+ per
condition. Error bars are +/- SEM. Bars with different letters are significantly different at p<0.05.
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Figure 4.6. Inhibition of p38 rescues histone acetylation and p21 expression. A. Model
representing IL-1β downstream target, p38, and effect on butyrate metabolism B. Model
representing inhibition of p38 rescues butyrate induced p21 expression C. Western blot assay
was employed to detect the expression of P-p38, p38, p21, β-actin, H3ac, and H3. D.
Quantification of p21 expression corrected with β-actin . Data points represents a standard mean
where n = 3+ per condition. Error bars are +/- SEM Bars with different letters are significantly
different at p<0.05.
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Figure 4.7. Inhibition of p38 rescues histone acetylation and p21 expression. A. Model
representing IL-1β downstream target, p38, and effect on butyrate metabolism B. Model
representing inhibition of p38 rescues butyrate induced p21 expression C. Western blot D.
quantification of p21 expression. Data points represents a standard mean where n = 3+ per
condition. Error bars are +/- SEM. Bars with different letters are significantly different at p<0.05.
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CHAPTER V

General Discussion
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Discussion
Previous studies examining the link between inflammation and cancer progression have
pointed towards pro-inflammatory cytokines, in part, as key mediators of this effect. Proinflammatory cytokines are elevated in the serum of many cancers [1-3]. They have been shown
to stimulate cancer cell survival mechanisms such as angiogenesis, cell proliferation, and even
alter nutrient utilization [4-7]. For example, butyrate, a short chain fatty acids derived from fiber
fermentation in the colon, is the preferred energy source of colonocytes and increases colonocyte
differentiation which may counter tumor proliferation [8]. Ex vivo studies using colonic biopsies
from healthy patients undergoing routine colonoscopy were incubated with the pro-inflammatory
cytokine, TNF-α, were found to significantly reduce butyrate oxidation [9]. These findings have
been confirmed by in vitro studies in which TNF-α and IL-1β significantly reduced butyrate
oxidation in colorectal cancer cell lines [10, 11]. Indeed, the effects of pro-inflammatory
cytokines appears to have a profound effect on butyrate oxidation in colonocytes.
The present data indicate that the pro-inflammatory cytokine, IL-1β, suppresses butyrate
oxidation in colonocytes. It is thought that factors that disrupt butyrate metabolism will interfere
with its anti-cancer effects. The mechanisms by which this pro-inflammatory cytokine alter
nutrient utilization have not been fully characterized. Emerging data have identified that proinflammatory cytokines affect mitochondrial metabolism and subsequently, nutrient metabolism
to promote cancer cell survival [7, 12, 13]. Our studies demonstrate the pro-inflammatory
cytokine, IL-1β, suppresses mitochondrial oxidation of butyrate and this results in butyrateresistant cell proliferation in the HCT116 cancerous colonocyte cell line.
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Effect of pro-inflammatory cytokines, IL-1β, on mitochondrial metabolism
Butyrate is known to be oxidized in the mitochondria. More specifically, it undergoes βoxidation to form two acetyl CoA that is used for almost exclusively for oxidative
phosphorylation [14, 15], whereas less than 2% is found in cellular lipids and histones.
Regardless, this study and others indicate that by controlling intracellular concentrations of
butyrate, such as by suppressing uptake or oxidation, cancer cells can diminish butyrate’s growth
inhibitory effects [10, 15]. In this study, we describe that pro-inflammatory cytokines may also
be able to alter butyrate’s fate and preserve cancer cell proliferation. Although this effect has
been seen in other models, the timeline and treatment conditions have not been well described [9,
10]. We demonstrate that IL-1β has an immediate effect on butyrate oxidation and more
importantly on mitochondrial function. In another study using hepatocytes, IL-1β was found to
perturb mitochondrial function resulting in a decreased oxygen consumption coupled with
upregulated proton leak [13]. In agreeance, we see in Chapters 2 and 4, that IL-1β inhibits
oxygen consumption and upregulates proton leak. We validated these effect by measuring
NADH and find that it is also diminished in the presence of IL-1β. This suggests that IL-1β
perturbs mitochondrial function and may facilitate a shift in metabolism towards upregulated
glycolysis. However, in our findings we did not see this shift towards increased glucose
consumption. On the contrary, we find that IL-1β suppressed glycolytic capacity as well. This
suggests that IL-1β may promote cancer cell survival through another means.
We postulate that by inhibiting IL-1β, we would be able to rescue butyrate’s growth
inhibitory effects. To do so we sought to determine the pathway that IL-1β would most likely
use. Towards this end we find that IL-1β utilized the interleukin-1 type I receptor (IL-1RI). IL-1β
is unique among the cytokines in that it has its own naturally expressed receptor antagonist,
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interleukin-1 receptor antagonist (IL-1RA) [16, 17]. Population studies find polymorphisms in
the IL-1RA gene are associated with an increase in cancer incidence [18]. In vivo studies
demonstrate that IL-1RA is able to negate cancer promoting effects of IL-1β and reduce cancer
progression in murine gastric cancer models [19]. Thus, it appears that IL-1RA would be able to
suppress IL-1β signal transduction. The present studies show that IL-1RI is the receptor that IL1β is using and that IL-1RA is able to inhibit IL-1β’s signal transduction resulting in rescued
butyrate oxidation. Furthermore, in Chapter 2, we find that neither butyrate or glucose oxidation
is affected by IL-1RA. This suggests that IL-1RA did not appear to perturb cancer cell
metabolism.
We next turned our focus to IL-1β’s mode of intracellular signal transduction. Previous
studies examining the link between IL-1β and cancer cell progression have pointed towards
NFκβ [20, 21]. NFκβ has been linked to promoting tumorigenesis in many cancers [20].
Furthermore, NFκβ has been linked to regulating energy homeostasis by regulating cytochrome c
oxidase [22]. For this reason, we chose to inhibit NFκβ by using a selective inhibitor, caffeic acid
phenethyl ester (CAPE). While we show that CAPE did block phosphorylation and activation of
NFκβ, it failed to rescue butyrate oxidation. This suggests that NFκβ, while activated by IL-1β, is
not a necessary component in mediating IL-1β’s effect on butyrate oxidation.
p38 has been previous linked to colorectal tumor progression [4, 23-25]. Specifically,
inhibition of p38 in patient derived xenografts slows tumor growth [24]. In vivo studies using
nude mice models of gastric adenocarcinoma indicate that IL-1β activates p38 thereby promoting
metastatic cancer progression [26]. In vitro studies using hepatocytes find p38 aids in the
regulation of hepatocyte metabolism [27]. These findings allude to p38 playing a role in cancer
metabolism and suggest a pathway in which IL-1β may utilize to shift colorectal cancer cell
123

metabolism away from butyrate utilization. In Chapter 2, the present data indicate that the
selective inhibition of p38, by SB203580, rescues butyrate oxidation. Furthermore, in Chapter 4,
we find that inhibition of p38 results in a rescue of mitochondrial function. Our data demonstrate
that IL-1β, in a p38-dependent mechanism, perturbs mitochondrial function resulting in
decreased butyrate oxidation. The mechanisms by which IL-1β perturbs butyrate utilization have
not been well characterized and may represent an interesting therapeutic target that could be
exploited to enhance butyrate utilization and therefore augment butyrate’s anti-cancer effects. To
this end we postulated that IL-1β may have downstream functional effects on suppressed
butyrate metabolism such as suppressing butyrate growth inhibitory properties.

Downstream consequences: Butyrate resistant cell proliferation
Previous studies have demonstrated the protective effect of butyrate on colorectal cancer
cell progression and have pointed to its role cell cycle regulation as the mediator of this effect. In
vivo studies using murine models receiving a high fiber or tributyrin (a butyrate analog) diet
displayed decreased incidence of colorectal neoplasia [28, 29]. In vitro studies corroborate these
findings and demonstrate butyrate’s ability to suppress cell proliferation in a p21-dependent
manner [30]. Therefore, this would suggest that butyrate has a profound effect on colorectal
cancer cell proliferation and any interruption of its growth inhibition effect may result in cancer
cell survival.
Butyrate is known to induce histone acetylation that, in part, induces expression of p21
[30-32]. More specifically, increased expression of p21 aids in the regulation of cell cycle and
can restrict cell cycle progression in the G1 phase or increased expression of p21 can stimulate
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apoptosis via a BAX/BIM mediated pathway [30-35]. Previous ex vivo studies in cardiac
myocytes have shown IL-1β to inhibit p21 expression, which enhances cell proliferation [36].
The mechanism by which IL-1β mediates this effect was not characterized, but alluded to that
fact that p21 expression was upregulated within the first eight hours of treatment [36]. Consistent
with these results we see that butyrate stimulates an increase in p21 expression in the first three
hours. Others have found that p21 is required for butyrate induced growth arrest [30]. To this end
we find that IL-1β suppresses p21 in our cancerous colonocytes in the presence of butyrate and
results in butyrate resistant cell proliferation.
In Chapter 2, we described that IL-1β could suppress butyrate oxidation. Previous studies
have shown that diminished butyrate oxidation results in increased intracellular butyrate
concentrations and leads to enhanced histone deacetylase (HDAC) inhibition [29, 37]. Towards
this end we predicted that IL-1β, by suppressing butyrate oxidation, would enhance global
histone acetylation and therefore increase butyrate’s growth inhibitory properties. However, we
find that IL-1β suppresses global histone acetylation. We next predicted that IL-1β would impact
butyrate’s HDAC inhibition activity. We find that IL-1β negatively impacted HDAC activity in
the presence of butyrate, but not by trichostatin A (TSA). This may be due to the fact that
previous studies have measured butyrate induced HDAC activity at a later time point and our
studies looked at these effects within a three-hour window. Additionally, others have shown that
pro-inflammatory cytokines downregulate butyrate uptake [10]. This is consistent in findings of
biopsies from patients with ulcerative colitis and inflammatory bowel disease treated with
inflammatory cytokines show diminished butyrate uptake and oxidation [14, 38].
Butyrate exclusively arrests cancer cell growth through increased p21 expression. The
mechanisms that regulate p21 are either dependent or independent of the tumor suppressor
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protein p53 [30]. The levels of p21 are highly controlled to ensure cell cycle checkpoints [33].
Previous studies show that p38 is linked to regulating p21 expression indirectly of p53 and in
human epidermal keratinocytes [39]. HCT116 cancer cells are wild type for p53 and therefore
perturbing p53 activity through p38 may represent a pathway for regulating p21 expression. In
Chapter 2 we find that inhibition of p38 rescued butyrate oxidation and therefore in Chapter 4,
we employed the same methodology and found that inhibition of p38 resulted in a rescue of
butyrate induced p21 expression. Furthermore, this rescued butyrate’s ability to induce growth
arrest resulting in a negation of IL-1β’s protective effect in butyrate-treated cells. The ability of
IL-1β to confer selective resistance to butyrate in these cancerous colonocytes is a prime
example of how cancer cells modulate their environment to ensure survival. Ultimately, this
confers a significant, selective advantage to cancerous colonocytes that promotes net cell growth.
These findings reveal novel insight as to how IL-1β can shift nutrient metabolism to support
cancer progression.

Pro-inflammatory cytokines acutely perturb cancer cell metabolism
Pro-inflammatory cytokines influence alterations in mitochondrial function [7, 13, 27]. In
Chapters 2 and 4, we see the direct, real-time effects that the pro-inflammatory cytokine, IL-1β,
can have on mitochondrial oxidation. The bioenergetics of tumor cells or oncobioenergetics is
influenced by a variety of factors and dynamically change in response to the cellular
microenvironment [12, 40, 41]. The use of FDG-PET/CT (fludeoxyglucose-positron emission
tomography/computerized tomography) scans are used to trace, visually, the uptake of a glucose
analog, FDG, and detect metabolically active malignant tissue [42, 43]. These types of studies
exploit the metabolic nature of cancer and are used to locate and stage cancer [42]. These studies
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show that many types of cancer cells have a phenotypic oncobioenergetic signature. We
hypothesize, due to our previous studies, that pro-inflammatory cytokines may also affect cancer
cell metabolism in other cancer cell lines and may have a metabolic phenotype. By
characterizing the effects of pro-inflammatory cytokines on cellular metabolism we may reveal
insight as to how cytokines can influence cancer cell metabolism.
Previous in vitro studies using prostate cancer cells lines determine that the
aggressiveness of the cancer cell line has a phenotypic oncobioenergetic profile [7]. The authors
postulate that the metabolic profile may be a useful parameter in predicting cancer invasiveness
i.e. aggression [7]. In Chapter 3, the data indicates that IL-1β does not affect butyrate oxidation
in non-colon cancer cells. However, IL-1β does affect endogenous substrate oxidation. In vitro
studies using late stage prostate cancer cell lines associated increased oxidative phosphorylation
with increased invasiveness [7]. In addition, in vivo murine studies demonstrate that IL-1β
promotes invasiveness and tumorigenesis [44-46]. This may be due to the ability of IL-1β to
enhance cancer cell metabolism to promote cancer progression by modifying mitochondrial
function. We find that IL-1β stimulates non-colon cancer cells to increase endogenous substrate
oxidation in the absence of glucose. This may mimic the tumor microenvironment in that tumors
often outgrow their blood supply and must rely on endogenous substrate utilization [6, 47, 48].
This may further allude to the fact that IL-1β is associated with stimulating angiogenesis,
adhesion molecules and metastasis as a way to support cancer cell survival [16, 41, 49]. More
studies like these are necessary to characterize the effects of pro-inflammatory cytokines on
cancer cell metabolism.
We find the differences in butyrate oxidation may be due to tissue type and/or the differentiation
capacity of these cancer cells. TNF-α has been shown to suppress butyrate oxidation in HT-29
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cells [10]. Accordingly, in Chapter 2, we tested if IL-1β would have the same effect and we
found that HT-29 colorectal cancer cells did not respond to IL-1β’s effect on butyrate oxidation
as the HCT116 cancer cell line did. Whereas, TNF-α also suppressed butyrate oxidation in
HCT116 cells. We postulate that this is due to genetic and differentiation differences as
demonstrated by the higher baseline levels of alkaline phosphatase found in HT-29 cells.
Likewise, others have found dissimilar disease pathology in HT-29 versus HCT116 cells, even
though both are colorectal cancer cell lines [50]. Our data represent a real-time view of proinflammatory cytokines affecting cellular metabolism in a cytokine and cell type dependent
manner. By reviewing Table 5.1 and 5.2, we can see that a variety of pro-inflammatory cytokines
have differing effects on butyrate and endogenous substrate oxidation.

Future Directions
We find that pro-inflammatory cytokines stimulate shifts in nutrient utilization to
promote cancer cell survival. Identification of the mechanisms associated with this need to be
more clearly understood. In the data presented here we have demonstrated that IL-1β, acting
through its receptor, suppressed butyrate oxidation in cancerous colonocytes which affected cell
cycle and proliferation rates through a p38 mediated mechanism. These studies provide a
comprehensive analysis of the effects that pro-inflammatory cytokines have on butyrate
metabolism in cancerous colonocytes.
Nevertheless, there is still more to be understood about the effect of pro-inflammatory
cytokines have on cancer cell metabolism. Especially, considering that inflammation is an
enabling characteristic of cancer initiation and progression. Furthermore, we have demonstrated
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here that IL-1β can modify cancer cell metabolism to increase chances of survival. Therefore, we
should seek to find our studies replicated and verified to validate our original research. To this
end it would be advantageous to determine which p38 isoform contributes IL-1β ability to
stimulate the shift in nutrient utilization. Furthermore, exploration methodologies that perturb
IL-1β ‘s signal in more complex system to test the pro-inflammatory cytokine butyrate
suppression effect is produced in these systems.

Conclusion
This dissertation project represents a comprehensive analysis of pro-inflammatory
cytokines effects on butyrate metabolism in the colorectal cancer cell line, HCT116. We
demonstrate that IL-1β perturbed butyrate metabolism resulting in increased cancer cell
proliferation in the colorectal cancer cell line HCT116. This project has identified two targets
through which IL-1β is mediating its signals; IL-1RI and p38. Ultimately, IL-1β confers a
selective advantage via p38 to avoid butyrate-induced p21 expression. These types of advantages
can lead to heterogeneous tumor populations filled with cells that have specialized traits to
promote tumorigenesis. Furthermore, these findings reveal novel insight as to how IL-1β can
modulate cancerous colonocyte metabolism to support cancer cell proliferation
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Appendix

Table 5.1. Pro-inflammatory cytokine effect on butyrate oxidation in different cancer cell
lines. (-) suppresses butyrate oxidation. (+) enhances butyrate oxidation. (NE) no effect. (ND)
not determined.

IL-1β

TNF-α

IL-6

HCT116

-

-

+

HT-29

NE

-

ND

A375

-

ND

ND

22Rv1

-

ND

ND

133

Table 5.2. IL-1β’s effect on endogenous substrate oxidation in different cancer cell lines. (-)
suppresses butyrate oxidation. (+) enhances butyrate oxidation. (NE) no effect. (ND) not
determined.

IL-1β
HCT116

+

HT-29

NE

A375

+

22Rv1

+
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